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Genetic aberration plays a fundamental role in the complexities of human
cancers. In order to understand cancer at its fundamentals, we aimed to study low
abundance genes which undergo genetic perturbations in cancer. Therefore, we
developed a method to discover low abundance, yet cancer specific genes in various
human cancers. Our strategy entails the modification of suppression subtractive
hybridization (SSH), allowing it to be used in conjunction with oligonucleotide arrays.
This novel method, termed modified SSH (mSSH), significantly enhanced the
detection sensitivity when used with oligonucleotide array (Affymetrix), while
retaining the major advantages of each system. Using mSSH, we generated 14
subtracted gene chips derived from three cancer types: Hepatocellular carcinoma
(HCC), Breast carcinoma, and Nasopharyngeal carcinoma (NPC). We identified gene
signatures specific to each cancer type, and a set of common genes that was found
to be up-regulated in all three cancer types. These signatures consist primarily of
genes with unknown functions, nonetheless, they are of biological relevance.
The highest expressed gene in the common set, FLJ11029, was selected for
further characterization. We discovered that FLJ11029 was a potent repressor for
MHCII genes, hence it was named Transcription Repressor of MHCII (TROM).
Expression of endogenous TROM is inversely correlated with respect to HLA-DRA’s
expression in cells treated with IFN, and in MHCII-deprived human tissues.
Furthermore, over-expression of TROM resulted in marked reduction of HLA-DRA
mRNA level, while silencing of TROM caused the enhancement of HLA-DRA
transcription. We found that TROM could regulate the expression of HLA-DRA by two
mechanisms. Firstly, TROM bound to the x1-box of the HLA-DRA promoter and
destabilized the enhanceosome, by competing against the regulatory factor X (RFX)
ix
and cyclic AMP response element binding protein (CREB). Secondly, TROM
deactivated STAT1, an upstream regulator of MHCII during the induction of IFN, and
contributed to its degradation through the proteosome pathway. Furthermore, we
were able to detect the repression of HLA-DRA by TROM in various human cancers,
inferring biological role of TROM in promoting immuno-escape by cancer cells.
Moreover, we observed a strong correlation of TROM with the advancement of
the disease in various cancers. We have also discovered the potential of TROM as a
strong prognostic marker that could predict survival in HCC and breast cancer. Even
in histologically difficult samples, TROM showed a remarkable predictive power that
gives additional information on patient survival, which could alter treatment
outcome.  In summary, we have isolated a novel gene, namely TROM, by using
mSSH. TROM exhibits strong attributes of a transcription repressor that down-
regulates MHCII in human cancers, which in turn promotes cancer formation and
progression.
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1.1 Low abundance genes, gene profiling and mSSH
1.1.1 Low abundance genes
An estimation of 300000 mRNA transcripts could be found in a typical single
living cell (1). To the surprise of many, majority of these transcripts are present in
very low copy numbers. The idea of low abundance transcripts was first suggested
in a study looking at the transcriptome of HeLa cells by Bishop et al. in the 1970s (2).
In that study, it was found that mRNA molecules are present in three distinct
frequency classes (Figure 1.1). Furthermore, both high copy number transcripts (104
copies/cell) and intermediate transcripts (500 copies/cell) are present in less than 1%
of the total number of transcripts; while the remainder of the mRNA transcripts are
present in low copy number (10 copies/cell). However, even with this discovery, low
abundance transcripts are traditionally treated as noise.
Recent studies confirmed the observation on low abundance genes that these
transcripts exist in large number in the transcriptome (3, 4). In the study of
Velculescu at al.(1), it was found that in both cancerous and normal human cell, over
95% of the transcriptome are present in low copy number (Table 1.1). Following that,
same observation was found in other species like Arabidopsis, Yeast and Drosophila (5-
7). Low abundance transcript therefore might play significant roles in cellular
process, and perhaps involve in shaping human diseases including malignancies.
Hence, it is important to systematically identify low abundance genes that are altered
in human disease.
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Figure 1.1 Three abundance classes of mRNA in HeLa cells.
The figure is an adaptation from Nature 250, 199-204
Table 1.1 Percentage of low abundance genes in human transcriptome.
The table was taken from Nature Genet. 23, 387-388
Copies/cell transcripts (%) mRNA mass (%) transcripts (%) mRNA mass (%) 
>500 0.1 20 0.04 18
50-500 1 27 0.4 27
5-50 9 30 4.6 30
<5 89.9 23 94.9 25
Colon cancer cells All tissues
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1.1.2 Low abundance genes in cancer
Applying gene expression analysis to identify genes that are commonly
deregulated in different tumor types may facilitate identification of targets for the
early diagnosis of cancer and of clinically relevant biological targets associated with
histological heterogeneity.  In recent studies, global gene expression analyses of
various human tumors have facilitated the identification of genetic profiles related to
tumor classification (7), disease outcome (8, 9), response to therapy (10, 11), and
novel therapeutic targets (12).  One of the key remaining challenges for genome-wide
gene-expression profiling is the assay of genes with rare transcripts. Recent evidence
showed that rare transcripts are widespread in human (6). Serial analysis of gene
expression (SAGE) is able to detect these transcripts at high sensitivity, but the
sequence information is too short to provide annotation meanings (13). Longer
sequence information detected using conventional microarray are useful, but even
Affymetrix can detect only less than 55% of the rare population (14
Retinoblastoma (RB) and p53 are prototypic low abundance genes that turned
out to be key players in cancer carcinogenesis (15, 16). The myriads of functions
played by these two genes showed that low abundance genes were not less
important than high abundance genes. Despite intensive effort on transcript
identification in cancers, little is known about the low abundance transcripts that are
altered during carcinogenesis. Identification and characterization of low abundance
gene that differentially displayed in cancer could help to discover new territories in
cancer genetic. Therefore, approaches featuring high throughput and high sensitivity
for detecting low-expression transcripts which are physiologically relevant are
urgently needed for functional genomic studies.
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1.1.3 Microarrays
Over the past decade, high throughput screening strategies have contributed
enormously to the fundamentals of molecular research.  These strategies have
enabled the examination of global mRNA expression profiles within a sample
simultaneously, and has benefited both the scientific and clinical community in
better understanding molecular pathways and mechanisms, diagnosis, disease
classification and treatment outcome prediction (30).
Essentially, all gene profiling microarrays are based on the hybridization of
nucleic acids. Since its introduction in year 1995, miroarrays has evolved into
different platforms, and it can now be categorized into two main systems; cDNA
microarrays, and oligonucleotide microarrays. cDNA microarray is constructed
using probes from PCR products amplifying cDNA clones, thus the probe sequence
can be up to a few thousands base pairs (31). On the other hand, oligonucleotide
microarray uses relatively short (25-70mer) probes, fabricated by in situ light directed
chemical synthesis. Both methods immobilize the probes onto a solid surface in an
array format. In oligonucleotide array, the probes are designed to be similar in their
hybridization characteristics including hybridization temperature and binding
affinity, hence providing comparable absolute measurement for each probe (32, 33).
The advantages of controlling these hybridization parameters could not be achieved
in cDNA microarray as each probe is different in spot size, sequence length and GC
content (30). Although each approach has its own requirements in sample processing
and data handling, and each obtain creditability and limitations that differ from one
another, oligonucleotide array is by far a better platform in terms of reproducibility
and sensitivity, due to the lack of concise kinetics in cDNA microarray.
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1.1.4 Suppression Subtractive Hybridization (SSH)
With a similar goal to that of microarray, suppression subtractive
hybridization (SSH) was developed in hope of isolating differentially expressed
genes in a certain pathophysiological condition. SSH is a global PCR-based technique
which combines cDNA subtraction with suppression PCR amplification (34).  The
subtraction ability of SSH relies on the hybridization of complementary cDNA
sequences from two biological samples being compared. With the effect of
suppression PCR, the subtracted sequences are further enriched. Suppression PCR is
mediated by long inverted terminal repeats, incorporated in the primer sequence.
When attached to the cDNA sequences, the primers form a panhandle-like structure
that inhibits further amplification. Common sequences in the same biological sample
will incorporate two suppression primers that promote the forming of the pan-
handle like structure.  Subsequently, the non-target cDNA are eliminated and the
selected cDNAs enriched (Figure 1.5).
In brief, the SSH procedure involves two successive tester-driver
hybridization steps, which lead to normalization of tester-specific molecules, hence
allowing the subsequent enrichment of low abundance, tester-specific transcripts
(Figure 1.2).  Accordingly, SSH offers a reliable strategy to systematically identify
cancer type-specific transcripts. It is known for its high sensitivity and efficiency in
detecting rare transcripts by using small amount of starting RNA. To provide a high-
throughput platform for the identification of differentially expressed genes, cDNA
libraries are constructed with the differentially expressed cDNA clones isolated
following SSH.  Once printed on chips, these cDNA clones serve as probes to screen
tumor or normal tissue samples that are hybridized as targets (35, 36).  However, the
main drawback of this approach is that the results are directly dependent on the
signal coming from the targets rather than the subtracted probes.  Hence, the original
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molecular complexity of the samples represented by the subtracted library is often
lost, rendering this approach ineffective for the detection of genes with low level of
expression.
Figure 1.2 Suppression Subtractive Hybridization.
Schematic representation of the SSH method described by Diatchenko et al. The figure
outlines the subtraction hybridization procedure, and the amplification of suppression PCR.
Figure 1.2
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1.1.5 modified Suppression Subtractive Hybridization (mSSH)
Gene profiling with the Affymetrix oligonucleotide arrays offers an alternate
platform which is more robust and allows the quantitation of mRNAs
simultaneously (37).  Despite its advantages, oligonucleotide arrays have not been
widely used in conjunction with SSH due to difficulties in generating anti-sense
RNA from the subtracted cDNAs. To combine the two methods, we develop a new
method termed modified Subtraction Subtractive Hybridization (mSSH), which
allows the generation of a single population of uni-directional cRNA from the
subtracted cDNAs, through in vitro transcripction.
The major challenge in combining the two techniques is to generate
unidirectional antisense RNA from the subtracted cDNAs through in vitro
transcription. RNA polymerases frequently used for in vitro transcription are T7, SP6
and T3 polymerase (38). These polymerases are DNA template dependent, and each
has specific promoter sequence and orientation requirements (Figure 1.3a). When a
polymerase binds to the double stranded promoter sequence, it uses the 3’-5’ DNA
strand as template and synthesizes a complementary 5’-3’ RNA strand (39). To
generate antisense RNA, the promoter sequence needs to get incorporated to the
non-coding DNA strand (Figure 1.3b). Affymetrix and other in vitro transcription
protocol generally use oligo(dT)-T7 promoter primer during reverse transcription
from total RNA. To enable the combination of SSH and oligonucleotide array, our
tasks are: a) the generation of antisense RNA from the subtracted cDNA, which does
not allow the priming of the above primer anymore; b) the generation of an
unidirectional pool of antisense RNA from the subtracted cDNA, and not a mixed
pool of sense and antisense RNA. A detailed description of this method will be
presented and discuss in Chapter 3.
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Figure 1.3 Paradigm of in vitro transcription.
a) The three bacteriophage polymerases each requires specific promoter sequence.
Underlined sequences indicate the minimum sequence needed for efficient
transcription. The bolded G is the first base incorporated into RNA during transcription.
This part of the figure was adapted from the Ambion website
(http://server1.ambion.com/techlib/basics/transcription).
b)  Schematic representation of the in vitro transcription of uni-directional antisense RNA.
T7-oligo dT primer were used in the first strand synthesis and the T7 promoter sequence
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In brief, to tackle these problems, we use the concept of oligo(dT)-T7 priming,
by incorporating the T7-promoter sequence to the non-coding cDNA strand during
the first strand synthesis at the very beginning of the subtraction procedure. We
linked T7-promoter sequence to the existing cDNA synthesis sequence (CDS) via a
RsaI digestion site, which allows us to exclude the CDS sequence during the
digestion step. In conventional SSH, the T7-promoter is introduced during the
adaptor ligation step which allows the generation of RNA via in vitro transcription,
but would yield both sense and antisense RNA, as the T7-promoter site is
incorporated to both coding and non-coding cDNAs. In mSSH, we avoided this
complication by changing the adaptor sequence to that of a SP6 promoter. This
replacement has an additional advantage of allowing synthesis of both senses of
RNA if desired, by simply switching the polymerase to SP6 instead of T7
polymerase.
mSSH retained the characteristic of conventional SSH, that is to subtract and
to normalize transcription abundance. However, when used in conjunction with
oligonucleotide array, mSSH gives the added advantage of allowing detection of low
abundance transcripts. In Chapter 3 of the thesis, we present evidence to
demonstrate that mSSH enhances the identification of low abundance transcripts
that are tumor-specific.  Specifically, we are able to demonstrate its usefulness and
feasibility in enriching low abundance tumor-specific transcripts from human
hepatocellular carcinoma (HCC), breast carcinoma, and nasopharyngeal carcinoma
(NPC) with this strategy.
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1.2 Cancer
1.2.1 Burden of Cancer: worldwide and local statistics
Failure in controlling cell growth, cell proliferation and cell death causes
cancer. The term itself brings anxiety to the patient and is equally distressing for the
family.  Globally, 24.6 millions of people are living in this distress, with 10 million
new cases being diagnosed each year (8). The cancer burden in each part of the world
is depicted in Figure 1.4. Cancer is the second most common cause of death world
wide, behind cardiovascular diseases. It was predicted that in year 2020, cancer will
become the leading cause of death with a mortality rate of 10.3 million people per
year, in addition to 16 million new cases each year (Figure 1.5). Among males, the
most common cancers are lung and stomach cancer, while breast cancer and cervical
carcinoma topped the chart for females. All together, lung, colorectal and stomach
cancers are the most common cancers for both sexes (1).
Asia has the most number of cases in incidence (45%), death (50%) and
prevalence (37%), when compared to the world data. Southeast Asia has an age
average rate (ASR) of 130 incidences per 100000 per year for male population, and
102 for female; meanwhile the world ASR is 209 for male and 160 for female.   In
Singapore, cancer death accounts for 30% of overall mortality, with the incidence rate
of 8000 per year, and increasing (9) (Table 1.2). The ASR for Singapore is relatively
high, rating at 226 for male and 202 for female, far exceeding the average ASR for the
world population. In this part of the world, colorectal cancer is the most common
cancer among the male, with breast cancer for females (Figure 1.6). However, lung
cancer has the highest mortality rate in both males and females.
The statistics shows that cancer is a profound disease with snowballing
incidence rate, both locally and worldwide. Urgent measures are needed to improve
the efficiency and success at the prevention, detection, and treatment.
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Figure 1.4  Worldwide cancer incidence.
The figure was excerpted from the World Health Organisation (WHO)  2007 report.
Figure 1.5  Predicted global mortality statistic.
The prediction was done according to projections carried out by WHO in year 2006.
Figure1.5
Figure 1.4
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Table 1.2 Incidence of cancers in Singapore.







Table 1.2a Incidence of cancers by gender in five-year period
Singapore, 1968-2002
Table 1.2b Incidence of cancers by years of diagnosis, 2001-2005
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       Figure 1.6  Ten most prevalent cancers in Singapore.
       The figures were excerpted from Singapore Interim Registry 2006
Figure 1.6
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1.2.2 Causes of cancer
Human cancer is a heterogeneous disease that differs widely in clinical
outcome and therapeutic response.  This heterogeneity is likely to reflect the
accumulation of numerous disparities including behavioural factors, environmental
stimuli, genetic aberrations and influences of the tumour microenvironments, which
contribute, or acquired throughout the multistage progression of cancer (3).
However, despite the heterogeneity, different cancers share a few common causal
reasons. Grossly, exposure to carcinogens, dietary habit, use of tobacco and the lack
of physical exercise all relate strongly to the formation of the disease (1).  From a
more refine perspective of molecular biologists, the manifestation of cancer requires
six essential changes at the cell physiology: 1) self-sufficiency in growth signals, 2)
insensitivity to growth inhibitory signals, 3) evasion of apoptosis 4) cell cycle
replication 5) angiogenesis, and 6) tissue invasion and metastasis (10). These changes
are essential in the common pathway of carcinogenesis. From a broader view, the
development of cancer is the result of deregulated immunity. Immune system can be
viewed as an extrinsic factor that is engaged after the tumour has bypassed the
intrinsic suppressors. Therefore, the deregulation of immune system can be seen as
the seventh hall mark of cancer (11). Together, these changes involve alterations in
the regulation of thousands of genes involved in the circuits of pathways that
intersect with one another (Figure 1.7).  Although quite a few key players involved in
these pathways have been studied extensively, there are still major gaps in the map
of carcinogenesis that need to be filled. Of the altered genes, low abundance genes
are a group of genes that was constantly being left out without giving much
attention, although the number of low abundance genes is big and they might be
playing a crucial part in the propagation of cancer (6).
                                                                                                   Section 1 Introduction
16
Given the high mortality and incident rate of cancer, it is of utmost
importance to prevent the issue from worsening.  Cancer incidents can be prevented
by controlling tobacco and alcohol consumption, moderate dieting and hepatitis B
vaccination (8). Meanwhile, cancer death can be reduced by early detection and
proper treatment regimens. For molecular scientists, this inspired thousands of
research projects searching for treatment targets and genetic signatures that are
altered in cancer patients, for early detection and choosing treatment options.
Figure 1.7
Figure 1.7  A demonstration of the integrated circuitry in carcinogenesis.
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1.2.3 Hepatocellular Carcinoma (HCC)
HCC is the 6th most common cancer worldwide (626000 new cases), with a
high death rate of 598000 each year. Southeast Asia is one of the regions that shows
high incidence for HCC, with an ASR of 18.2, and a sex ratio of 2.4 (male:female). In
Singapore, it is a leading cancer that tops the chart for both incidence and mortality
rate (12, 13).
Hepatitis B (HBV) and hepatitis C (HCV) viruses, together with alcohol
consumption, are the most relevant risk factors for HCC. Other causes include
Aflatoxin exposure, iron deposition, cirrhosis, tobacco and alcohol consumption (14).
For HCC, these risk factors are geographically dependent. In Europe and Japan,
alcohol and HCV infection are equally important as risk factors; elsewhere in Asia,
HBV alone contributes to 70% of the cases; while a high rate of Aflatoxin B1 (AFB1)
intake, a substance produced by fungi which contaminates food source, was
observed in Southeast Asia.
Curative treatments of HCC are surgical resection, liver transplantation and
percutaneous ablation. Hepatic resection remains the first option for patients without
extrahepatic metastasis. The survival of the candidates is high, around 60%-70% at 5
years, but the recurrence rate is equally high (>50% at 3 years), making it the biggest
drawback for this therapeutic option (15). On the other hand, transplantation as a
treatment option has lesser recurrence rate than surgery, with a 4-year survival of up
to 85%. However, donor shortage and graft rejection remain the biggest challenge.
Ethanol injection and radiofrequency ablation are techniques used in percutaneous
treatments. These ablations are ultrasound image guided, and yield response rate of
80%. Although this method fails to provide local control, it is still an effective option
when surgery is not feasible.
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p53 and -catenin are the two most frequently mutated genes in HCC. -
catenin is a central player in Wnt signalling pathway, where its activation promotes
cell proliferation, motility and morphology changes (16). HCC associated -catenin
mutations have been found within exon 3 of the gene, where the mutants would be
more stable and hence prolong the Wnt signalling pathway. On another hand, p53
mutations are associated with genomic instability, where allelic losses on
chromosome 1p, 4q, 6q, 9p, 13q, 16p, 16q, and 17p, are frequently observed in HCC.
In Asia, the mutation frequency of p53 is up to 33% and it generally occurs near the
cluster of exon 5 to 9. However, in regions where Aflatoxin B1 is prevalent, p53
mutation occurs at a specific hot-spot, codon 249 of exon 7 (21). This mutant
promotes proliferation and inhibits wild type p53-mediated apoptosis, thus
contributes to the loss of p53 function and deregulated cell cycle control.
Consequently, with over-expression of oncogenes and under-expression of tumour
suppressors, it further promotes tumour growth and the formation of higher stage
HCC.
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1.2.4 Breast Cancer
To date, breast cancer is the most prevalent cancer worldwide (23% of all
cancer), with 1.15 million new cases diagnosed each year. It is the fifth cause of death
among all cancers. The annual incidence is increasing at a rate of 0.5% globally, and
at 4% in Asia, making the estimated new cases at 1.5 million in year 2010 (1).
At present, the epidemiology of breast cancer is still largely unknown.
However, hereditary genetic aberrations are likely to be among the major risk
factors. Large-scale studies have identified a few genes which showed SNPs and
allelic changes, namely fibroblast growth factor receptor 2 (FGFR2), mitogen-
activated kinase kinase kinase 1 (MAP3K1), and caspase 8 (CASP8) (17). Although
the mechanism of these variants in tumorigenesis is still not known, they could be
used as screening markers to identify high risk individuals.
The mortality rate of breast cancer has declined in recent years, attributed to
early detection and advancement in treatment options. Surgical resection of the
primary tumor means mastectomy and axillary lymph node dissection in the past.
Breast conservancy surgery which includes lumpectomy followed by radiation
treatment, is now a better option after trials demonstrated that the local recurrence
rate and overall survival are similar in both resection techniques. For patients with
advanced disease (stage IIb or III), chemotherapy or hormonal treatment is given
before surgery (neoadjuvant therapy) to reduce the tumor size, and often receive
better prognosis (18).
Breast cancer is a heterogenous disease at both clinical and molecular level
and has since warranted continual studies to understand the disparities. Currently,
Estrogen receptor (ER) and human epidermal factor receptor 2 (HER2) are the most
distinctive prognostic markers (19). Breast cancers that are ER positive have a lower
mortality risk when compared to the negative. On the other hand, HER2 positive
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tumours are associated with poorer prognosis, high-grade tumours, lymph node
involvement and recurrence.  Although these markers are part of routine clinical
testing, they have not been able to explain the heterogeneity of breast cancer in
response to different treatments. More recently, large-scale gene profiling assays
have revealed five major molecular subtypes of breast cancer, which correspond to
prognosis (20). Overall, basal-like tumour has the worst prognosis and luminal A
type the best; and that HER2+/ER- and luminal B subtypes have a worse disease
course than normal breast-like tumours (17, 21).  This indicates a myriad of genetic
changes underlying the disease that need more detailed studies to predict treatment
response.
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1.2.5 Nasopharyngeal Carcinoma (NPC)
NPC is a unique malignancy that has distinctive geographical distribution
and it is ethnic dependent. The disease is rare in most part of the world (0.7% of all
cancer incidence), but highly prevalent among people in Southern China, Southeast
Asia, Northeast India, North Africa and among the Innuits. In these regions, the
incidence is approximately 30-80 per 100000 people per year (13).
NPC is a carcinoma originating from the epithelium of the nasopharynx.
Epidemiological studies have revealed that genetic susceptibility, dietary habits and
Epstein-Barr Virus (EBV) infection, are the three main aetiological factors for NPC
(22). The high incidence in Cantonese speaking group strongly suggests that genetic
susceptibility and dietary habit are interrelated to each other in causing the
formation of NPC. Human leukocyte antigen (HLA) is found to be strongly
associated with NPC in this ethnic group, particularly HLA A*2027 and HLA B*4601,
which show increased risk with the disease (23). Furthermore, salted fish and
preserved food that form daily diets in this population are full of nitrosamine, a
mutagenic agent.  Beside these factors, EBV infection is equally important. The viral
genome of EBV is found in every malignant epithelial cell, but not in surrounding
normal cells, or infiltrating lymphocytes. However, over 95% of the world
population are healthy carriers of EBV, indicating that the viruses were reactivated
by combinatorial factors in the host, which might be associated with the first two risk
factors.
   Unlike HCC and breast cancer, surgery is not a viable treatment option for
NPC due to inadequate resection margins. Conversely, radiation therapy has been
shown to achieve extremely good local control, at a rate that exceeds 90% (23).
However, even at this rate, distant metastasis and local recurrence remain relatively
significant. To improve outcome, concurrent chemotherapy and radiotherapy have
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been employed in randomized trials and resulted in improved overall survival (23,
24). The common drugs for NPC patients are cisplatin, bleomycin, doxorubicin,
epirubicin, 5-flourouracil, methotrexate and mitoxantrone.
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1.3 Major Histocompatibility Class II (MHCII)
Major Histocompatility Complex class II (MHCII) molecules are surface
glycoproteins which are constitutively expressed on thymic epithelial cells (TECs)
and antigen presenting cells (APCs), namely B-cells, macrophages, and dendritic
cells (25, 26). In human, there are three types of MHCII dimers, namely HLA-DR,
HLA-DP and HLA-DQ. The MHCII heterodimeric molecules consist of  and  chain
that are encoded by separate A and B genes (41).  These molecules play a pivotal role
in immune response by presenting intracellular molecules to the CD4+ T cells, which
in turn regulate adaptive immunity (27, 28). This MHCII-mediated peptide
presentation pathway participates in T cell-activation, differentiation and
proliferation, and in shaping the T-cell repertoire (29). As a result, deregulation of
MHCII severely impairs the immune system. Its alteration could either lead to
autoimmunity, or failure in the induction of immune response.
1.3.1 Regulation of MHCII transcription
The mode of MHCII expression can be categorized into constitutive and
inducible. Constitutive expression is restricted to TECs and APCs while inducible
expression can be observed in non-TECs by exposure to cytokines. In both expression
modes, the regulation is controlled at the transcriptional level. An interesting feature
of MHCII transcription regulation is that the class II genes share a conserved
promoter (30, 31). The architecture of the class II genes is formed by three conserved
elements, the S/W, X and Y boxes, where each is bound by specific transcription
activators (Figure 1.8). RFX complex recognises and binds the x1-box (32, 33), whereas
CREB occupies X2-box just downstream of x1-box (34). Meanwhile, nuclear factor Y
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(NFY), a complex which consists of A, B and C subunits binds to Y box (35, 36); and a
yet to be identified factor sits on the S box. These binding factors and their elements
form a stereospecific arrangement on the promoter, named as the enhanceosome (37)
(Figure 1.9). Enhanceosome activity depends on the synergistic binding of all the
activators and omission of any of these factors from the promoter leads to
transcription silencing.
Figure 1.8 Genetic organisation of MHCII promoter.
The MHCII promoters are conserved between different molecules, including HLA-DR, DP,
and DQ.
Figure 1.8
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       Figure 1.9
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        Figure 1.9 Transcription activation of MHCII promoter
The transcriptional activation of MHCII is a result of
synergetic effect of the enhanceosome members. These
member including RFX, CREB, NFY and CIITA.
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1.3.2 IFN and MHCII
Apart from APCs and TECs, non-thymic derived cell types are able to express
MHCII under the induction of IFN.  IFN ligand binding to its receptors result in the
activation of the Jak-Stat pathway (38, 39). Upon IFN induction, Jak1 and Jak2 are
recruited to the oligomerized receptors and phosphorylate the tyrosine 440 of the
IFN receptor subunit 1 (IFNGR1). This in turn provides a docking site for Stat1 and
subsequently caused the phosphorylation at tyrosine 701 and serine 727 residues.
The phosphorylated Stat1 then dimerizes and translocates to the nucleus, and
induces the IFN responsive genes upstream of MHCII activation. The cascading
activation events following IFN finally lead to the activation of MHCII (40, 41) (
Figure 1.10).
Nature Review Immunology 2005 5 795-806
        Figure 1.10 Activation of MHCII by IFN.
Figure 1.10
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1.3.3 MHCII and cancer
Human cancers with low expression of HLA-DR have long been
documented, and there is increasing evidence of a relationship between HLA down-
regulation and prognosis. In Diffuse large B-cell lymphoma (DLBCL), HLA-DR is
often highlighted as an important prognosis factor, and an indicator for malignancy
(42-45). In solid tumours, down regulation of MHCII correlates with recurrance and
metastatic progression (46). Tumour cells expressed Tumour Antigens (TA) which
are not found on normal tissues. These antigen is presented via both MHC class I
and class II molecules, and activate both CD4+ and CD8+ T cells (47).  Specifically for
MHC class II, the TAs are gp100 (48), MAGE-1,MAGE-3 (49), Tyrosinase (50) and
NY-ESO-1 (51). By suppressing the expression of MHCII, these TA could not be
presented to the CD4+ T cells. Hence, the expression of MHCII on the tumour cells
renders these diseased cells direct lysis targets for CD4+ T cells ((52, 53); meanwhile
MHCII modulates CD4+ T helper cells activation which facilitates optimal priming of
tumour-specific cytotoxic CD8+ T cells (54, 55). As a consequence, tumour cells
expressing MHCII can evoke immune response; on the contrary, the loss of MHCII
expression can result in immune escape. However, despite the importance of the loss
of MHCII in human cancers, the molecular mechanism that precedes the events is
not well understood.
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1.4 Aims
Cancer is a complex and multifactorial disease. With the worldwide burden
of cancer increasing each day, it is of utmost urgency to understand the disease, so as
to give better prevention measures, and to have higher success rate at treatment of
the disease. Gene profiling inarguably accelerates the process of acquiring insights
into the pathologenesis of cancer. However, low abundance genes have often being
left out in these profiling analyses. We aimed to establish a versatile method that can
identify low abundance yet differentially regulated genes in cancers, in a high
throughput fashion. By the development of mSSH, we hope that it could aid in the
search for more elusive perturbations that ultimately drive a normal cell onto the
path of becoming a neoplastic cell. By using three types of human cancers (HCC,
breast cancer and NPC), we hope to identify altered genes that are cancer-type
specific and also commonly change in all types of human cancers.
TROM is identified by mSSH as a novel cancer-specific transcript that is low
abundance. In search of its function, we hope to illustrate the importance of low
abundance genes in the process of carcinogenesis, and to highlight the potential of
these genes as cancer markers.
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2.1 Methods and reagents
2.1.1 Cell culture
Raji, Jurkat, and Daudi were purchased from ATCC. CNE2, MCF-7, 293T and
PLC/PRF/5 were gifts from various labs in NCC. Raji and CNE2 were maintained in
RPMI 1640 medium supplemented with 2mM L-glutamine, 1mM sodium pyruvate, and
10% heat-inactivated fetal bovine serum. MCF-7, 293T and PLC/PRF/5 were grown in
DMEM supplemented with 2mM L-glutamine, 2mM sodium pyruvate and 10% fetal
bovine serum. All the cells were grown at 37°C with 5% CO2. Raji cells were transiently
transfected using the Nucleofactor Device (Amaxa Biosystem, Gaithersburg, MD, USA)
with 1x106 cells/transfection. Other cells were transfected with Lipofectamine and Plus
reagent (Invitrogen) with 2μg of pcDNA-TROM, or pcDNA empty vector. Cells were
harvested after 48 h for analysis. For induction of IFN, cells were first treated with IFN
(100U/ml) for 24 h, and then transfected with the plasmids for another 48 h before
analysis. siRNA transfections were performed on cells using Lipofectamine RNAiMax
(Invitrogen), according to the recommended protocol. siRNAs were purchased from
Invitrogen.
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2.1.2 Tissue specimens
All tissue biopsies studied were from the Tissue Repository, National Cancer
Centre Singapore, after obtaining approvals from both the Tissue Repository
Management Committee and the Institutional Ethics Committee.  Biopsies were
collected from patients only after informed consents were given.  Cancer tissues and
adjacent non-cancerous tissues were collected from five patients with hepatocellular
carcinoma (HBV+) and five patients with invasive carcinoma of the breast: three with
infiltrating ductal carcinoma, one with infiltrating lobular carcinoma and one with
medullary carcinoma of the breast.  The biopsies collected were immediately snap-
frozen in liquid nitrogen.  Biopsies from four patients diagnosed with undifferentiated
nasopharyngeal carcinoma (WHO Type III) as well as five nasopharyngeal biopsies that
are histologically negative for NPC were also collected.  All NPC biopsies were obtained
as endoscopic bites and preserved immediately in RNALater (Ambiom, Foster City).
The five specimens that were histologically negative for NPC were pooled and
employed as normal nasal epithelial tissues for mSSH.
2.1.3 Total RNA isolation
RNA isolation was carried out with Trizol Reagent (Gibco) according to the
manufacturer’s  instruction. Briefly, 2x107 number of cells were harvested and lysed in 1
ml Trizol reagent. The lysate were homogenised and incubated at RT for 5min. 0.3ml of
chloroform (Sigma) was added, followed by vigorous shaking and incubation at r.t. for 5
min. The samples were centrifuged at 12000 g for 15 min at 4°C. The Upper aqueos
phase was transferred to a fresh tube and 0.7ml isopropyl alcohol (Sigma) was added to
precipitate RNA. The samples were incubated at RT for 10 min, followed by
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centrifugation at 12000g for 10min at 4°C. The RNA precipitates were washed with 75%
ethanol and re-centrifuged at 7500g for 5 min at 4°C. The air-dried RNA pellets were
resuspended in DEPC-treated water.
2.1.4 Reversed transcription (RT)
All reagents and reactions were kept on ice when possible. 5μg of total RNA was
mixed with 2μl of 60ng/μl random hexamer (Invitrogen), 1μl of 500ng/μl oligo-dT12-18
(Invitrogen) and 9μl of DEPC H2O in a total reaction volume of 12μl and incubated at
70°C for 10 min before immediately chilling on ice. 1μl of 10mM dNTP (Promega), 2μl of
0.1M DTT, 4μl of 5x DNA synthesis buffer and 1μl of Superscript II reverse transcriptase
(200U/μl) (Invitrogen) was then added to the denatured RNA. The reverse transcription
reaction was carried out at 25°C for 10 min, 42°C for 90min and 80°C for 10min. 1μl of
cDNA was used as template for PCR or real-time PCR.
2.1.5 Polymerase Chain Reaction (PCR)
PCR reactions were carried out in a Hybaid PCR machine, with each mixture
containing: 1x Taq Polymerase buffer, 50μM dNTPs, 1.5μM MgCl2, 0.25μM primer mix
and 5 units of Taq Polymerase (Promega). The PCR cycling was as follow: Initiation at
94°C for 2 min, annealing (55-60°C) for 1 min, extension at 72°C for 2 min, followed by
25-30 cycles of 94°C (1min), 55-60°C (1 min), and 72°C (1min). This is completed with a
final extension of 72°C for 10min.For PCR expression cloning, Advantaq (Clontech)
polymerase with proof reading activity was used. The cycling used was: 95°C (1 min), 18
cycles of 95°C (30 sec) and 60°C (1.5min), completed with 60°C 10 min.
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2.1.6 Real-time PCR
Gene expression were quantified by real-time PCR on RotorGene 3000 system
(Corbett Research). QuantiTectTM SYBR Green PCR Kit (Qiagen) was used for single
colour detection. 1 μ l of cDNA was mixed with 4μ l of 10μM primer mix, 10μ l of
QuantiTectTM SYBR Green master mix and  5μl autoclaved distilled H2O (ddH2O). PCR
cycler was as follow: 95°C (15 min), 94°C (15 sec), 58-60°C (30 sec), 76°C (30 sec), 50
cycles starting step two, and followed by melting curve analysis starting from 65°C to
95°C. The results obtained were analysed using the RotorGene 4.0 software.  All sample
Ct values were normalized against 18sRNA and expressed as 2-Ct to calculate the
differences in fold changes.
Multiplex real-time PCR was performed with molecular beacons designed
specifically for HLA-DRA and FLJ11029. QuantiTect Multiplex PCR NoRox Kit(Qiagen)
and RoterGene(Corbett) were used for the analysis. 18s was used as internal control for
normalization. The cycling for the real-time PCR was as follow: 95°C (15 min), 94°C (45
sec), 56°C (45 sec), 76°C (45 sec), 50 cycles starting step two, and followed by melting
curve analysis starting from 65°C to 95°C.
2.1.7 Rapid Amplification of cDNA Ends (RACE)
5’ and 3’RACE was used to determine the 5’and 3’ end of the FLJ11029 gene.
5’RACE and 3’RACE system was purchased from Invitrogen and performed as
manufacturer’s instruction. FLJ11029 specific primer 2R and 4R were used for 5’RACE,
and primer 7F and 4F were used for 3’RACE. Separate RACE were performed from 293T
cells and HepG2 cells. 5μg total RNA from each cells were reversed transcribed and
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used for both 5’ and 3’ RACE. The PCR products from the two cells were subcloned into
pCR2.1 vector, both strands sequenced and compared.
2.1.8 TOPO TA cloning
PCR products were cloned into a pCR2.1 TOPO vector using the TOPO TA
cloning kit (Invitrogen). 4ul of PCR products were mixed gently with 1ul of salt solution
and 1ul of pCR2.1-TOPO vector, incubated for 30min at r.t., and chilled on ice. One shot
chemical competent E.coli  was thawed on ice, and 2ul of the reaction mixture was added
to the competent cells, mixed and incubated for 25 min on ice. The cells were heat
shocked at 42°C for 30 sec and immediately cooled on ice for 2 min. 200ul of SOC media
was then added to the cells for recovery. After shaking at 200 rpm for 1hr at 37°C, 50ul
of the transformation mixture was spread on a prewarmed 50ug/ml Ampicillin
containing LB plate, with X-gal and IPTG. The plate was incubated overnight at 37°C.
2.1.9 Plasmid isolation
Single colony was inoculated into 200-400ml selective LB broth and grown at
37°C for 16h with vigorous shaking (~240 rpm). Plasmids from the bacteria culture were
isolated using Qiagen Plasmid Endofree Maxi Kit according to the manufacturer’s
instruction.
2.1.10 DNA sequencing
DNA sequencing was performed using the ABI PRISM BigDye Terminator v1.1
cycle sequencing Ready Reactioin Kit (Applied Biosystem). 100ng of PCR products or
200-500ng of plasmid DNA in a volume of 5ul was mixed with 4ul of BigDye reaction
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mixture, 1ul of 10uM primer and incubated for 25 cyles of 96°C (10 sec), 50°C (5 sec), and
60°C (4min). The reaction mixture was precipitated with 10ul of ddH2O, 2ul of 3M
sodium acetate and 50ul of 95% ethanol for 15min at r.t., and centrifuged at 13000rpm
for 20min at r.t.. The pellet was washed with 250ul of 70% ethanol and air-dried before
resuspending in 15ul of ABI loading solution and denatured at 95°C for 5 min. Each
sample was analysed on the ABI PRISM 377XL automated sequencer.
2.1.11 modified Suppressive Subtractive Hybridization (mSSH)
Cancerous and adjacent non-cancerous normal liver tissues from HCC patients
were used for the mSSH procedure. The mSSH procedure was done according to the
Clontech PCR-Select cDNA subtraction kit protocol with customized primers, as listed
in Chapter 2.2.  Briefly, 1μg of total RNA was reversed transcribed using T7 promoter
primer with CDS (cDNA sequence) to generate first strand cDNA conjugated with T7
promoter sequences at its 5’ end at the non-coding strand. Each cancerous (tester) and
normal (driver) samples were prepared in separate tubes. Each reaction contained 1μg
total RNA, 1μM primer, 2μl 5x first-strand buffer, 1μM dNTP mix, and 20U AMV
reverse transcriptase made up to a total of 10μl with ddH2O. The reaction was incubated
for 42°C for 1.5 h. This was followed by second-strand cDNA synthesis and
phenol/choloroform purification. 48.5μl ddH2O, 16μl 5x second strand buffer, 1.6μl
10mM dNTP mix and 4μl 20x second strand enzyme cocktail were used in each second
strand reaction, and were incubated at 16°C for 2 h. 2μl T4 DNA polymerase was added
at the end of the reaction for an additional 30 min. 4μl of 20x EDTA/glycogen was
added after the T4 DNA polymerase incubation, to end the reaction. Following which
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100μl phenol: chloroform: isoamyl alcohol (25:24:1, Invitrogen) was added and the
reaction was vortexed vigorously, before centrifugation for 10 min at 13000 rpm in a
bench-top centrifuge. This step was repeated with 24:1 chloroform: isoamyl alcohol
before precipitation with 40μl ammonium acetate and 300μl 95% ethanol, centrifugation
at 13000rpm, washing the pellet with 80% ethanol and air drying at rt. Pellet was re-
suspended in 50μl ddH2O. Purified cDNAs were then digested with RsaI restriction
enzyme to generate shorter cDNA fragments ranging from 0.1 to 1kb in size, that are
suitable for adaptor ligation. Each digestion reaction contained 43.5μl purified cDNA,
5μl 10x RsaI restriction buffer and 1.5μl RsaI enzyme (10U/μl) and was incubated at 37°C
for 1.5 h. Phenol: chloroform extraction was then performed as described above. Air-
dried pellet was re-suspended in 5.5μl ddH2O. Customized adaptor 1 and 2 (listed in
Chapter 2.2 page 53) were ligated onto the tester cDNA, while driver cDNA was not
ligated. Tester cDNA was separated into two reactions to ligate with 2 different adaptors
(adaptor 1 and 2). In each reaction, 2μl RsaI-digested and -purified cDNA was mixed
with 2μl of adaptors (10μM), 2μl 5x ligation buffer, 1μl T4 DNA ligase (400U/μl) and 3μl
ddH2O and incubated at 16°C overnight. To stop the reaction, 1μl of EDTA/glycogen
was added, and the reaction was heated at 72°C for 5 min. Following this, two
subtraction hybridization steps were performed. 2μl digested and purified driver cDNA
was mixed with 1μl of each adaptor-ligated tester cDNA saperately, and mixed with 1μl
of 4x hybridization buffer, making a total of 4μl for each reaction. The reactions were
then heated at 95°C for 5min, followed by an 8 h incubation at 68°C. The second
hybridization was performed by combining the two subtracted populations, and went
for further subtraction with excessive driver cDNA. 1μl of fresh driver cDNA, 1μl of
each subtracted samples, 1μl of 4x hybridization buffer and 2μl ddH2O were mixed and
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incubated at 68°C overnight. After the subtraction hybridization step was completed, the
suppression PCR step commenced. 1μl of the subtracted cDNA was added to 19.5μl
ddH2O, 2.5μl 10x PCR reaction buffer, 0.5μl dNTP mix (10mM), 1μl customized PCR
primer 1 (Chapter 2.2) (10μM), and 0.5μl 50x Advantage cDNA polymerase. The PCR
cycling was: 94°C for 25 sec, followed by 27 cycles of 94°C for 10 sec, 66°C for 30 sec and
72°C for 1.5 min. 3μl of the PCR product was then diluted with 27μl of ddH2O, and 1μl
of the diluted product was then used in a secondary PCR reaction. 1μl of the diluted
product was added to 18.5μl ddH2O, 2.5μl 10x PCR buffer, 1μl of each nested PCR
primers (provided in the kit), 0.5μl dNTP mix (10μM) and 0.5μl 50x Advantage cDNA
polymerase mix. Cycling used was: 10 cycles of 94°C for 10 sec, 68°C for 30 sec amd 72°C
for 1.5 min. A total of 5 secondary PCR reactions were performed and pooled for in vitro
transcription in the Affymetrix GeneChip protocol.
2.1.12 Affymetrix GeneChip
All steps were performed in accordance to protocols provided by Affymetrix Inc.
(Santa Clara, CA). Briefly, 5ug of total RNA was converted to double stranded cDNA
using T7-(dT)24 primer (Invitrogen). The cDNA was in vitro transcribed into biotinylated
complementary RNA (cRNA) by incorporating biotin-CTP and biotin-UTP using
GeneChip IVT labelling kit (Affymetrix). Biotinylated cRNA was then fragmented into
sequences at the length of 40-100 bases. 10ug of fragmented cRNA was hybridized to
Affymetrix GeneChip Human U133A and U133B arrays for 16 h at 45°C with constant
rotation at 60 rpm. After washing, the hybridized gene chips were sequentially stained
with streptavidin-phycoerythin (Invitrogen), biotinylated goat anti-streptavidin (Vector
Laboratories, Burlingame, CA) and streptavidin-phytoerythin for a second time, for
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signal amplification. Washes and staining procedures were then performed on an
Affymetrix fluidic station and the gene chips were scanned with the Gene Array
confocal scanner (Agilent). Raw expression data were analyzed using Affymetrix
Microarray Suite version 4.0 (MAS 5). One-sided Wilcoxon’s signed rank test was used
to calculate the differences between PM-MM for a particular probe set.  We have chosen
the default parameter of 1 = 0.05 and 2 = 0.065 and   = 0.015 for the determination of
the Present/Absent call of the probe sets.  Further analyses were made using the Cluster
and Treeview software (M.Eisen, http://rana.lbl.gov/), GeneData Expressionist Suite
(GeneData AG), and Partek Genomic Suite (Partek Inc, Missouri).  The selected genes
were annotated using the Affymetrix NetAffxTM analysis system
(http://www.affymetrix.com).
2.1.13 Electromobility Shift Assay (EMSA)
Synthetic oligonucleotides were purchased from 1st Base (BaseAsia, Singapore)
and annealed for 2h at rt. EMSA were performed with the LightShiftTM
chemiluminescent EMSA kit (Pierce), following manufacturer’s protocol. In summary,
binding reactions were carried out for 30min at r.t. with 20fmol of biotin-end-labeled
target DNA and 5μg of TROM. Assays were loaded onto native 5% native
polyacrylamide gels in 0.5x Tris borate/EDTA and electrophoresed at 100V. The gels
were then transferred onto a Hybond N+ (Amersham) membrane in 0.5x Tris
borate/EDTA at 100V for 30min. Transferred DNAs were cross-linked to the membrane
at 120mJ/cm2 and detected using horseradish peroxidase-conjugated.
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2.1.14 Promoter Pull Down Assay
5’ biotinylated dsDNAs (2.5 pmole) were commercially synthesized, and were
coupled to Streptavidin-coated magnetic beads (Promega) according to the
manufacturer’s protocol. Whole cell extracts (1mg) were diluted to 35μl in binding
buffer and incubated with DNA template for 2 h at 4°C. The beads were washed three
times with wash buffers and the bound proteins eluted with SDS-PAGE sample buffer,
by boiling of the beads at 98°C for 5 min, and analysed by western blotting.
2.1.15  Immunofloresence Microscopy
Cells were plated on 24mm coverslips and transfected as above and fixed with
3.7% formaldehyde in PBS for 10 min at rt. After fixation, cells were washed three times
with PBS and incubated for 10 min in 0.1% Triton X-100 at r.t.. Cells were further washed
three times in PBS and blocked for non-specific staining in PBS with 10% FBS at rt for 1
h. Cells were then incubated overnight with primary antibodies at 4°C. After incubation
with secondary antibody at rt for 1 h, coverslips were washed in PBS and mounted onto
slides with 4,6-diamidino-2-phenylindole containing VECTASHIELD with DAPI (Vector
Laboratories). Slides were examined using the LSM-510 laser-scanning confocal
microscope (Carl Zeiss).  Alexa-flour 488-conjugated and Alexa flour-546 conjugated
goat anti-mouse or goat anti-rabbit (Molecular Probes) were used as secondary
antibodies. For assays involving IFN, cells were treated witih IFN for another 24 h
after transfection. For inhibition assays, cells were treated with proteosome or lysosome
or calpain inhibitors for 16 h before fixation. MG132, lactacystin, NH4Cl, Chloroquine
and ALLN were purchased from Sigma.
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2.1.16  Chromatin ImmunoPrecipitation (ChIP)
ChIP was performed with the Ez ChIP kit (Upstate Biotechnology), in accordance
with manufacturers’ recommendations. Briefly, 2x107 of cells in 4.875ml of culture
medium were cross-linked by adding 125μ l 40% formaldehyde, making a final
concentration of 1% formaldehyde. Cross-linking was carried out for 10 min at rt and
stopped with 0.125M glycine. Cross-linked cells were washed twice in ice cold PBS (all
steps onwards were performed on ice), and the cells were scrapped in lysis buffer
(provided in kit). 5 min centrifugation at 5000rpm were performed at 4°C to pellet the
nuclei. The pelleted nuclei were resuspended in nuclei lysis buffer (provided in kit) and
incubated for 10 min. The released chromatin was then sheared to an average size of
300-1000 base pairs by sonication. The sheared chromatin preparation was pre-cleared
and immunoprecipitated with 10μg of antibodies at 4°C overnight. The
immunoprecipitated complexes were reversed cross-linked at 65°C over night and
subjected to real-time PCR analysis.
2.1.17 Ubiquitin Assay
Transfected cells were treated with 5μM MG132 for 16 h prior to harvest. The
cells were lysed in Lysis Buffer containing 6M Guanidinium-HCl, 0.1M
Na2HPO4/NaH2PO4, pH 8.0,10mM imidazole. The lysate was sonicated in pulses (3x5
sec) to shear the genomic DNA and incubated with 100ul of 50% slurry nickel-NTA-
agarose (Qiagen) with rotation for 3hrs, at r.t.. The beads were washed twice with lysis
buffer, twice with Wash Buffer I containing lysis buffer diluted in 25mM Tris-HCl at 1:4
ratio, pH 6.8, 20mM imidazole, and twice with Wash Buffer II containing 25mM Tris-
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HCl at 1:4 ratio, pH 6.8, 20mM imidazole. Precipitated ubiquitinated proteins were
eluted by boiling beads in 2x SDS sample buffer and analysed by immunoblotting.
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2.2 Buffers
2.2.1 Buffers for Agarose Gel Electrophoresis
10x TBE  - 0.89M Tris, O.89M Boric acid, 0.02M EDTA
10x Sample Loading Buffer  - 0.25% (w/v) Bromophenol Blue, 0.25% (w/v) Xylene
Cynol, 50% (v/v) Glycerol
2.2.2 Buffers for Western Blotting
Lysis Buffer – 10mM Tris-HCl (pH 7.4), 150mM NaCl, 1mM EDTA, 1% Triton X –100,
0.5% NP-40, 1x Complete protease inhibitor cocktail (Roche)
2x Sample Buffer –  0.215M Tris, pH 6.8, 4% (w/v) SDS, 20% (v/v) Glycerol, 2% (v/v) -
mercaptoethanol, 0.005% (w/v) Bromophenol blue
10x Electrophoresis Buffer – 25mM Tris, pH 7, 250 mM Glycine, 0.1% SDS
1x Transfer Buffer  - 39mM Glycine, 48mM Tris-Base,0.037% (w/v) SDS, 20% methanol
1x Tris/CAPS buffer – 10mM 3-[cyclohexylamino] - 1- propane sulfonic acid, pH 11 with
NaOH, 10% methanol
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Lower Tris, pH 8.8 – 1.5 M Tris Base, 0.4% (w/v) SDS, adjusted to pH 8.8 with conc. HCl
Upper Tris, pH 6.8 – 0.5 M Tris Base, 0.4% (w/v) SDS, adjusted to pH 6.8 with conc. HCl
Stripping Buffer – 100mM -mercaptoethanol, 62.5mM Tris-Hcl, pH 7, 2% SDS; or
Restore Stripping Buffer (PIERCE)
Blocking Buffer – 5% skim milk, 0.05% Tween 20in PBS
SDS-PAGE Gels – 30% Acrylamide/ Bis solution 37.5: 1
2.2.3 Buffers for Ubiquitination Assay
Lysis Buffer G – 6M Guanidinium-HCl, 0.1M Na2HPO4/NaH2PO4, pH 8.0,10mM
imidazole
Wash Buffer I – Buffer G diluted in 25mM Tris-HCl at 1:4 ratio, pH 6.8, 20mM imidazole
Wash Buffer II – 25mM Tris-HCl, pH 6.8, 20mM imidazole
Elution Buffer (2x SDS sample buffer) – 90mM Tris HCl, pH 6.8, 20% (v/v) Glycerol, 2%
(w/v) SDS, 0.1 M EDTA, 0.1M EDTA, 0.1M DTT, 0.02% (w/v) Bromophenol Blue
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2.2.4 Buffers for promoter Pull down Assay
Binding Buffer - 20mM HEPES pH 7.9, 6mM MgCl2, 1mM DTT, 100mM KCl, 20%
Glycerol, 0.01% NP-40, 0.15mg/ml poly dIdC, 0.15mg/ml Ecoli ssDNA, 1x Complete
protease inhibitor cocktail (Roche)
Wash Buffer – Binding Buffer added with 1mg/ml BSA
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2.3 Primers and siRNA sequences
2.3.1 Primer and adaptor sequences modified for mSSH
1. T7 promoter primer with cDNA synthesis sequence (CDS)
2. PCR primer 1
3. Adaptor 1
4. Adaptor 2








CDS                                                                         T7 promoter
RsaI
5’ ATTTAGGTGACACTATAGAAGAGCGGGTCGCGGCCGAGGT  3’
SP6 promotor
3’ GCCGGCTCCA  5’
EagI
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2.3.2 Primers for 5’ and 3’ RACE, RT-PCR, and real-time PCR
Primers for 5’ RACE
2 R  5’ CAGTTCTGGCACCAGCTGTA 3’
4R 5’ CTCGGTGGCAGATACGAGAT 3’
Primers for 3’ RACE
7F 5’ AGCTTATACCATCGCCGAAA 3’
4F 5’ AAGCTCCAGGAAGCTGAA 3’
Primers for RT-PCR and real-time PCR
HLA-DRA F 5’ AGACAAGTTCACCCCACCAG 3’
HLA-DRA R 5’AGCATCAAACTCCCAGTGCT 3’
FLJ11029 F 5’AGCTTATACCATCGCCGAAA 3’
FLJ11029 R 5’ CTGGGCTCCTCTCTACATCG 3’
NFX F 5’CCTTGGCAGAAATTGAGGAA 3’
NFX R 5’ TTTGGTACTTTCGGGTCCAG 3’
RFX  F 5’ CACCATGGCAGAAGATGAGCCTG 3’
RFX R 5’ TGGGGGTGTTGCTTTTGGG 3’
NFY F 5’ GTGGTGAAGGTGGACGATTT 3’
NFY R 5’ ACTTCAATTTGCCAGGCATC 3’
CREB F 5’ACTGTAACGGTGCCAACTCC 3’,
CREB R 5’ TCCATCAGTGGTCTGTGCAT 3’
STAT1 F 5’ CCGTTTTCATGACCTCCTGT 3’
STAT1 R 5’ TGAATATTCCCCGACTGAGC 3’
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ACTB F 5’ CACCATGGATGATGATATCGC 3’
ACTB R 5’CTAGAAGCATTTGCGGTGGAC 3’
18sRNA F 5’CCTGCGGCTTAATTTGACTC-3'
18S RNA R 5'-CGCTGAGCCAGTCAGTGTAG 3'
2.3.3 Probe sequences used in multiplex real-time PCR
HLA-DRA  F    5’   GTCACCACAGGAGTGTCAGAG  3’,
HLA-DRA R 5' (Cy5)CGCGATCGACCACCTTTTCCGCAAGTTCCACTAGATCGCG
(BHQ) 3’;
FLJ11029     F   5’  ATGTAGAGAGGAGCCCAGGTG   3’,
FLJ11029  R 5' (FAM) CGCGATCCGTCATCACTGGAGTCAGTCCTGTTCGATCGCG
(BHQ) 3’;
18s RNA     F   5’ GATGCGGCGGCGTTATTCC 3’,
18s RNA  R 5' (JOE) CGCGATCAAAGACTTTGGTTTCCCGGAAGCTGCGATCGCG
(BHQ) 3’.
2.3.4  Promoter sequence used for EMSA
x1  box : 5'biotin-CCTTCCCCTAGCAACAGATGCGTC3'
cold x1 box: 5'CCTTCCCCTAGCAACAGATGCGTC3'
cold Y box : 5’AAATATTTTTCTGATTGGCCAAAGAGT3’
cold S  box:  5’TGTGTCCTGGACCCTTTGCAAGA3’
                                                                                                          Section 2 Materials & Methods
55
2.3.5 siRNA






Stealth negative control (medium GC) was purchased from Invitrogen.
SECTION 3
Chapter 3. Isolation of low abundance and
differentially expressed genes in cancers by
using modified Suppresion Subtractive
Hybridization (mSSH)
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3.1 Summary
Neoplasms are both clonal and heterogeneous. The disparities among different
cancers are often phenotypically and genetically distinct, reflected by the origin of the
cancer cells. Each malignancy was shaped by continuous renewal and remodelling of
the neoplasm during adaptation with the microenviroment. In such complexity, a
minute change at the basal level could avalanche into clinical manifestation. Hence,
disruption of such imperative factors often results in uncontrollable cascading events
that lead to the formation of cancer. However, mass screening of low abundance
transcripts is often obstructed by the limitation of current profiling methods. In this
study, we have designed a strategy, termed modified suppression subtractive
hybridization (mSSH), to identify genes encoding rare transcripts that are differentially
regulated in cancers.  The strategy entails incorporating the T7-promoter sequence at the
5’end of the non-coding cDNA strand during first strand cDNA synthesis to generate
uni-directional anti-sense RNA from the resultant cDNA following conventional SSH.
These transcripts were subsequently analyzed by Affymetrix oligonucleotide gene
arrays. We have used five hepatocellular carcinoma (HCC) as testers and the
corresponding normals as drivers to enrich for low abundance tumour type-specific
transcripts. The total number of detectable probe sets following mSSH was reduced
significantly in comparison to those detected for the same resected tumour tissues
without undergoing subtraction, thus yielding a high subtraction efficacy.  Moreover,
the enrichment of rare transcript was observed to be exceeded one thousand folds.
Using this experimental approach, we employed another five breast cancer and
four nasopharygeal carcinoma (NPC) biopsies as testers and their corresponding
normals as drivers, to select cancer type-specific, and common causal genes in
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tumorigenesis. We have identified 48 HCC-specific, 45 breast carcinoma-specific, and 83
NPC-specific genes.  In addition, 115 genes were up-regulated in all the three cancer
types.  When compared to gene-profiling data obtained without mSSH, the majority of
these identified transcripts were of low abundance in the original cancer tissues.  mSSH
can therefore serve as a comprehensive molecular strategy for pursuing functional
genomic studies of human cancers.
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3.2 Results
3.2.1 Development and construction of the mSSH strategy
 
To combine SSH and oligonucleotide array, our major challenge is to generate a
single population of uni-direction cRNA from subtracted cDNA. Hence, two specific
modifications were made to conventional SSH. Firstly, a modified T7-promoter primer
with CDS sequence was introduced during the first strand synthesis, to incorporate T7-
promoter into the 5’ end of the non-coding DNA strand (Figure 3.1). Secondly, SP6-
promoter was used as the adaptor sequence in place of the T7-promoter used in
conventional SSH (Figure 3.1). Unlike the conventional SSH which introduces T7-
promoter to both coding and non-coding cDNA strand; these modifications ensure and
secure the position of the T7-promoter only on the non-coding cDNA strand, generating
a single anti-sense RNA population that can be analyzed with oligonucleotide arrays,
which could not be achieved with the conventional SSH method.
To identify differentially up-regulated tumor-specific genes, forward
subtractions with tumor RNA as tester and normal RNA as driver were performed.  Five
independent mSSH runs were performed with five independent pairs of human HCC
biopsies as testers and their corresponding histological normal tissues as drivers. The
samples were subjected to mSSH procedure as described in Materials and Methods.
Prior to digestion with RsaI, the cDNAs ranged in size from 0.5 to 10kb, whereas
following digestion, majority of the cDNAs were between 0.1 to 2kb in size.  Tumor-
specific fragments were subsequently generated by primary PCR and secondary nested
PCR using tester-specific fragments obtained after two cycles of hybridization between
tester and driver cDNAs (Figure 3.1).  By inserting the T7-promoter sequence at the 5’
end of the non-coding cDNA strand during first strand cDNA synthesis, unidirectional
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anti-sense RNAs could be synthesized from the subtracted cDNAs.  Routinely, 80μg of
cRNA could be obtained from a typical subtracted sample.  Unidirectional cRNAs
generated from the subtracted cDNA were hybridized to Affymetrix HG U133A and
U133B oligonucleotide probe arrays.
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Figure 3.1  Schematic representation of the mSSH procedures.
Five independent mSSH runs were performed with five independent pairs of human HCC biopsies as testers
and their corresponding histological normal tissues as drivers. Tumour-specific fragments were subsequently
generated by primary PCR and secondary nested PCR using tester-specific fragments obtained after two cycles
of hybridization between tester and driver cDNAs.  By inserting the T7-promoter sequence at the 5’-end of the
non-coding cDNA strand during first strand cDNA synthesis, unidirectional anti-sense RNAs could be
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3.2.2 mSSH depletes over 90% of the transcripts in tumour samples
To assess the efficiency of mSSH and to compare the nature of the transcripts
with or without mSSH, cRNAs from the same five HCC biopsies and their
corresponding five normal tissues were prepared individually and hybridized directly
to the Affymetrix HG U133A and B arrays without subtraction.  These results were
compared with those obtained from mSSH using identical HCC tumour and normal
samples.  Without mSSH, the average total number of probe sets detected for the five
HCC tumour biopsies L49, L52, L53, L57 and L60 was 14810, or 33% of the total available
probe sets on the Affymetrix HG U113A and B probe arrays (Table 3.1).  Following
mSSH, the total number of probe sets detected was reduced to approximately 1778, or
4% of the total available probe sets on the Affymetrix HG U133A and B arrays. Together,
there was a 90% reduction in the number of probe sets after subtraction. The reduction
of detectable probe sets after mSSH implicated the subtraction of common sequences
between tumour and normal.  When analysed for the background signals, we found that
the noise remained relatively low (<100) for all five HCC samples studied, before and
after mSSH (Table 3.2).
A total of 1944, 1716, 2036, 1479 and 1714 probe sets could be detected with
Affymetrix HG U133 sets following mSSH for sample L49, L52, L53, L57 and L60,
respectively (Table 3.1).  When the presence or absence of these transcripts were
analyzed using direct hybridization without mSSH, it was determined that 732 (39%),
755 (44%), 836 (42%), 693 (47%) and 673 (41%) probe sets were classified as absent for
L49, L52, L53, L57 and L60, respectively. The % were obtained by dividing the number
of absent genes (732) before mSSH to the number of present genes (1944 after adding up
U133A and U133B chips) after mSSH. For example, (732/1944) x 100% = 39%. These
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probe sets were therefore “lost” when conventional expression profiling studies had
been performed.
To confirm the efficacy of mSSH, we analyzed the 100 housekeeping genes
available on the Affymetrix HG U133A and B probe arrays.  Following mSSH, only two
of the 100 housekeeping genes could be detected in the subtracted HCC samples.  These
two genes were the ribosomal protein 4 (RLP4) and the anaphase promoting complex
subunit 5 (APC5), their signal intensities in the five subtracted liver samples were listed
in Figure 3.2a, whenever the genes were classified as ‘present’.  The efficiency of
subtraction following mSSH for the 100 housekeeping genes was also confirmed to be
over 90%.  In a follow-up analysis, two housekeeping genes, -actin and glyceraldehyde-
3-phosphodehydrogenase (GAPDH), were used as internal references to demonstrate
that RLP4 and APC5 which had been detected in the subtracted samples were in fact up-
regulated in HCC using real-time PCR and independent HCC samples (Figure 3.2b).
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Using one-sided Wilcoson’s signed rank test, a probe set is given a ‘present’ call if its P value
between PM-MM is less than 0.05, with 1=0.05 2=0.065 and =0.015. Absent probe sets were
not included in this table.
The background noise of the subtracted and unsubtracted samples were obtained using
Affymetrix MAS 5. The comparison showed that there were no significant differences between
the unsubtracted samples and the samples undergone mSSH.
Table 3.2 Comparison of background noise in subtracted and unsubtracted samples
sample ID HG-U133A HG-U133B
Tumor Normal mSSH Tumor Normal mSSH
L49 62 56 52 53 87 45
L52 60 65 77 52 55 59
L53 71 61 67 58 68 53
L57 56 56 60 74 75 56
L60 65 66 70 85 81 53
Table3.1 Number of probe sets detected before and after mSSH
Sample ID Tumour Normal  mSSH Tumour Normal mSSH
L49 8854 8339 981 5898 4233 963
L52 9618 8771 1131 5881 4864 585
L53 8823 8050 976 5174 4054 1060
L57 8864 9730 733 5196 5225 746
L60 10140 10184 922 5603 5867 792
HG-U133A                           HG-U133B
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Figure 3.2 Subtraction efficacy of mSSH
a) Of the 100 house keeping genes, RLP4 and APC5 were identified by mSSH to be up-regulated in
tumor, their signal intensities were listed together with two controls, ACTB and GAPDH. – denotes
‘Absent’ call . b) Real-time PCR were performed for all of the four genes, the results indicated up-
regulations of the identified gene (i) in tumor, and no change for the control genes (ii).
Sample ID RPL4 APC5 ACTB GAPDH
L49 1800 62500 - -
L52 1227 3073 - -
L53 211445 20983 - -
L57 - 3512 - -
L60 - - - -
a. Signal intensities of the house-keeping genes after mSSH
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3.2.3 mSSH amplified the signals of low abundance tumour-specific transcripts.
Figure 3.3 Distribution of signal intensities of the probe sets detected before and after mSSH.
The signal distributions of five liver samples were plotted with variances and medians indicated.
Prior to mSSH, the distribution of the signal intensities following hybridization
conformed to a normal distribution (Figure 3.3).  However, following mSSH, the overall
intensities of the signals were both shifted and skewed towards high levels.  Specifically,
for the five pairs of HCC samples examined, the medians of the signal intensities
detected was approximately 700 before mSSH, in comparison to 1500 after mSSH (750 to
1596, 758 to 1270, 770 to 1453, 788 to 1597, and 770 to 1666; for L49, L52, L53, L57 and L60
respectively) (Figure 3.3). The shifting of signal intensities of probe sets showed that
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For a detailed analysis, signal intensities of all the probe sets detected after mSSH
were traced back to their original signal obtained without mSSH. A summary of the
change of signal intensities before and after mSSH of all the 5 samples is tabulated in
Table 3.3. On average, 53% of the probe sets yielded signal intensities between 0 and 500
before mSSH and only 3% of the probe sets had signal intensities in this range following
mSSH.  Interestingly, no probe set presented a signal intensity over 100,000 before
mSSH, whereas more than 2% of the probe sets were detected with signal intensity more
than 100,000 after mSSH.
Specifically, for sample L49 (Table 3.4), 916 out of 1892 probe sets were detected
in the signal range 0 - 500 before mSSH.  Following mSSH, only 26 of these 916 probe
sets (2%) remained in the same 0 – 500 signal range.  The signal intensities for the other
880 probe sets shifted to higher levels following mSSH: 257 probe sets (20%) were in the
signal range 501 -1000, 583 probe sets (62%) had signals in the range 1001 - 5000, 23
probe sets (5%) had signals in the range 5001 - 10,000, and 27 probe sets (11%) had
signals over 10,000.  Similar signal amplification could be detected for samples L52, L53,
L57 and L60.  Thus, mSSH appears to amplify the intensity of detectable signals for
tumour-specific transcripts that were originally of low signal intensities.
Table 3.3  Total percentages of probe sets according to their signal intensities before and after mSSH
       Signal Intensity  
Before After Before After Before After Before After Before After 
0-500 48 2 61 3 49 4 55 1 52 3
501-1000 25 20 18 28 24 25 22 19 22 22
1001-5000 21 62 16 59 21 58 19 66 2 54
5001-10000 3 5 2 4 2 4 3 6 3 6
10001-50000 2 5 3 4 4 6 2 5 3 7
50001-100000 0 2 0 1 0 1 0 1 0 2
>100000 0 4 0 1 0 2 0 1 0 4
L49 (%) L57 (%) L60 (%) L52 (%) L53 (%)
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Each row designates the number of probe sets detected for a given signal range before mSSH,
whereas each column represents the number of probe sets detected after mSSH for the given
range. The total number of probe set detected in each sample were highlighted in bold.
Table 3.4 Distribution of probe sets according to their signal intensities before and after mSSH 
(i) L49
Original Signal 0-500 501-1000 1001-5000 5001-10000 10001-50000 50001-100000 >100000 Total
0-500 26 257 583 23 19 2 6 916
501-1000 6 82 329 29 20 4 7 477
1001-5000 3 49 232 31 48 20 25 408
5001-10000 1 6 14 7 5 4 12 49
10001-50000 0 3 12 1 5 3 18 42
50001-100000 0 0 0 0 0 0 0 0
>100000 0 0 0 0 0 0 0 0
Total 36 397 1170 91 97 33 68 1892
(ii) L52
Original Signal 0-500 501-1000 1001-5000 5001-10000 10001-50000 50001-100000 >100000 Total
0-500 42 326 620 25 12 0 4 1029
501-1000 4 76 189 17 12 0 2 300
1001-5000 10 64 134 25 30 4 0 267
5001-10000 0 5 16 2 6 0 4 33
10001-50000 0 1 23 5 9 2 2 42
50001-100000 0 0 0 0 0 0 0 0
>100000 0 0 0 0 0 0 0 0
Total 56 472 982 74 69 6 12 1671
(iii) L53
Original Signal 0-500 501-1000 1001-5000 5001-10000 10001-50000 50001-100000 >100000 Total
0-500 58 287 570 26 34 6 7 988
501-1000 6 107 299 19 32 2 7 472
1001-5000 9 87 230 25 39 8 21 419
5001-10000 0 10 14 3 5 0 4 36
10001-50000 0 8 27 10 18 3 7 73
50001-100000 0 0 0 0 0 2 0 2
>100000 0 0 0 0 0 0 0 0
Total 73 499 1140 83 128 21 46 1990
(iv) L57
Original Signal 0-500 501-1000 1001-5000 5001-10000 10001-50000 50001-100000 >100000 Total
0-500 14 182 530 39 13 1 5 784
501-1000 0 50 222 24 19 3 1 319
1001-5000 2 39 165 17 33 11 4 271
5001-10000 0 3 20 1 2 0 1 27
10001-50000 0 2 12 3 6 1 5 29
50001-100000 0 0 0 0 0 2 0 2
>100000 0 0 0 1 1 0 0 2
Total 16 276 949 85 74 18 16 1434
(v) L60
Original Signal 0-500 501-1000 1001-5000 5001-10000 10001-50000 50001-100000 >100000 Total
0-500 42 224 490 41 35 8 9 849
501-1000 7 81 209 22 21 10 10 360
1001-5000 8 52 151 25 46 17 31 330
5001-10000 1 11 14 6 11 1 6 50
10001-50000 1 2 20 9 11 3 7 53
50001-100000 0 0 1 0 3 0 0 4
>100000 0 0 0 0 0 0 0 0
Total 59 370 885 103 127 39 63 1646
Signal intensity after mSSH
No of Probe Sets after mSSH
Signal intensity after mSSH
No of Probe Sets after mSSH
No of Probe Sets after mSSH
Signal intensity after mSSH
No of Probe Sets after mSSH
Signal intensity after mSSH
No of Probe Sets after mSSH
Signal intensity after mSSH
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3.2.4 Identification of differentially expressed cancer type-specific transcripts.
After demonstrating that mSSH could permit the identification of transcripts that
are of low abundance, we proceeded to study different tumour types with mSSH, with
the objective of identifying genes that are both frequently and specifically deregulated in
these different malignancies.  Such knowledge has the potential to facilitate the
identification of targets for cancer diagnosis and therapeutic treatments.  For this
purpose, in addition to the 5 pairs of HCC samples studied above, 5 breast cancer
biopsies and 4 NPC cancer biopsies were also employed individually for mSSH using
the corresponding adjacent normal breast tissues as the drivers for breast cancer tissues
and pooled normal nasal tissues as the driver for NPC (Table 3.5).
After mSSH, the three data sets were comparatively analyzed to identify gene
expression patterns that were unique and common to each tumour type.  Data included
in the analysis were required to fulfill the following criterias. Firstly, for each cancer
type, a probe set would only be considered as consistently positive and be included in
our analyses if the probe set was present in more than 70% of the samples studied.  The
data obtained were then further classified into specific cancer sub-groups.  Secondly, a
probe set would be classified as “specific” for a tumour type when it was present in over
70% of samples studied for that particular tumour type (N4 for HCC and breast cancer,
and N3 for NPC), and was absent in more than 80% of the other types of cancers
studied (N7).  Thirdly, a probe set would be considered to be up-regulated in two types
of cancers if it was present in over 70% of samples for the two types of cancers studied
and was absent in more than 80% of samples for the third type of cancer studied.  And
lastly, probe sets that were present in greater than 70% of all subtracted samples were
considered as common probe sets for all three tumour types, i.e., HCC, breast carcinoma
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and NPC.  Probe sets that failed to meet any of the aforementioned criteria were
excluded from subsequent analyses.
The samples were obtained from the Tissue Repository of National Cancer Centre with informed
consent from the patients. The histology of all the samples studied was confirmed by qualified
pathologists. For the HCC and breast cancer samples, they were ascertained to consist of more
than 70% of the tumour tissues, and the normal samples were free of tumor cells. For the NPC
samples, due to small size of the specimens, pathology assessment was carried out on
independent adjacent samples. However, to rule out molecular contributions from non-tumorous
components as much as possible, the normal samples were obtained from immune tissues of
suspected NPC cases but histologically normal tissues. AFP = alpha fetoprotein; ER= Estrogen
receptor; PR= progesterone receptor; IDC= invasive ductal carcinoma; MC= multicentric
carcinoma; ILC= invasive lobular carcinoma.
Table 3.5 Histopathological information of the samples employed in mSSH
Clinical information of HCC patients
Sample ID Gender Age Grade HepatitisB Vascular Invation AFP
L49 M 72 2-4 - - 4
L52 M 49 2-3 + - 9064
L53 M 58 2 + + 6
L57 M 79 1 - + 15
L60 M 67 1 + + 4
Clinical information of Breast cancer patients
Sample ID Gender Age Type ER status PR status
B1 F 62 IDC - -
B3 F 36 MC n.a. n.a.
B4 F 80 IDC - -
B6 F 30 ILC + +
B8 F 47 IDC n.a. n.a.
Clinical information of NPC patients and normal individuals
Sample ID Gender Age WHO Type Differentiation
SC15 M 45 III undifferentiated
SC16 M 46 III undifferentiated
SC17 M 39 III undifferentiated
SC6 F 40 III undifferentiated
CG2 M 64 normal n.a.
SC4 M 34 normal n.a.
CG3 F 57 normal n.a.
SC5 F 27 normal n.a.
SC7 F 32 normal n.a.
                                                                                                                  Section 3 Results : mSSH
71
After the filtering processes, 48 probe sets were classified as HCC-specific, 45 as
breast carcinoma-specific, and 83 as NPC-specific.  A further 115 probe sets were
simultaneously up-regulated in all three cancer types (Figure 3.4a). Clustering analysis
was used to examine the expression patterns of these cancer-type specific genes in all
subtracted samples. As depicted in Figure 3.4b, the three clusters did not overlap with
each other. These genes, together with their functional annotations, are listed in Table
3.6. A combined total of 291 tumour type-specific and common genes identified by
mSSH were submitted to the Cancer Genome Anatomy (CGAP) Serial Analysis Genome
Expression (SAGE) database (1) to independently analyse their relative abundances.  269
of the identified transcripts were listed in the cancer SAGE database (Figure 3.4c). Over
70% of the 269 transcripts were found to be of low abundance, whereas less than 4% of
the transcripts identified were of high abundance. Specifically, 35 out of 44 mapped
HCC probe sets fall in the range of 0-7 tags/200000. Similarly, 25 out of 38; 51 out of 75;
and 84 out of 112 mapped probe sets were in the same low abundance category for
breast cancer-, NPC- and the common cancer gene signature. This comparison both
confirmed and extended our conclusion that mSSH can preferentially enrich low
abundance transcripts.
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Figure 3.4 Characterization of the cancer type-specific and common probe sets obtained
after mSSH..  a) Venn Diagram showing the unique and overlapping probe sets obtained after
mSSH for the three types of cancer studied.  b) Gene clustering experiments showing the three
groups of cancer type-specific genes after mSSH.  Each row represents an individual probe set
and each column represents an individual subtracted sample.  Pseudo-colours indicate
differential expression after mSSH; Black = absent, and Red = present. c) Correlation of the
abundance of the probe sets identified by mSSH with the Serial Analysis Genome Expression
(SAGE) database. SAGE ranges at 7/200000 tags and below were arbitrarily assigned as low
abundance, ARF1and GRIND2D were known low abundance genes that fall in this range;
SAGE ranges 64/200000tags and above were assigned as high abundance, GADPH and ACTB
were genes that fall in these SAGE ranges.
Figure 3.4c
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3.2.5 Validation of the gene signatures
To validate the biological relevance of the transcripts identified using mSSH, we
performed real-time PCR for the ten highest expressed genes from the 48-HCC signature
and the 115-common genes. Consistent with the mSSH results, realtime-PCR confirmed
that all but two of the top ten genes from the 48- HCC signature (204954_s_at and
235402_s_at) were preferentially expressed in HCC (Figure 3.5a).  Similarly, real-time
PCR analysis of the top ten expressed genes among the 115 common cancer type
transcripts demonstrated that they were all up-regulated in each of the three types of
cancer studied (Figure 3.5b).  For further validation on the gene signatures, clustering
analysis was performed on an independent and larger cohort of patients. Using the 48-
gene member HCC-specific signature, 24 new independent liver samples were correctly
segregated into clusters that separate 12 tumour biopsies and 12 normal samples (Figure
3.6a(i)).  Similarly, with the 45-member breast carcinoma-specific signature, 28
independent breast samples comprising 18 tumour and 10 normal samples were
correctly segregated (Figure 3.6a(ii)); while the 83-member NPC-specific signature was
able to segregate an independent 21 samples into 14 NPC tumour biopsies and 7 normal
biopsies (Figure 3.6a(iii)).  The 115 transcripts that could be identified in all three tumour
types following mSSH were also able to segregate most of the three different types of
cancer studied from the normal tissues when subjected to clustering analysis (Figure
3.6b (i), (ii), and (iii)).  These data confirmed that both the common and unique cancer-
specific transcripts identified by mSSH were biologically relevant.
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Figure 3.5  Real-time PCR of the identified gene signatures.
a) Real-time PCR analysis of the top ten probe sets, with the highest expression
after mSSH, selected from the 48 HCC-specific probe sets, and b) the 115 common
probe sets.  Fold change were expressed as 2-Ct comparing each tumour samples
to its normal. Green = higher expression in normal; Red = higher expression in
tumour. HCC signature genes were specifically up-regulated in HCC samples,
while common signature genes were up-regulated in all three cancers (HCC,
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Figure 3.6 Hierarchical clustering of the gene signatures on independent data sets.
a) Unsupervised hierarchical clustering analysis was performed on new independent tumour
samples using (i) 48 HCC-specific probe sets against 24 liver samples; (ii) 45 breast cancer-specific
genes against 28 breast samples; and (iii) 83 NPC-specific probe sets against 21 nasopharynx
samples.  Blue = normal samples; Red = cancerous samples.  b) Unsupervised hierarchical
clustering analysis using the samples in (a) and the 115 common probe sets that were up-regulated
in all three cancer types. Both specific and common cancer signatures were able to segregate
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The probe sets were annotated using Affymetrix NetAffx TM analysis system on the web site
http://www.affymetrix.com.
Table3.6  Functional annotations of probe sets identified by mSSH
A. 48 HCC-specific probe sets B. 45 Breast cancer-specific probe sets
Probe Set ID UniGene ID Gene Symbol Probe Set ID UniGene ID Gene Symbol
Fatty acid metabolism Cytoskeleton
209309_at 546239 AZGP1 227330_x_at 487562 LOC389833 
204257_at 21765 FADS3 229748_x_at 487562 LOC389833
234009_at 153322 PLCL1 242240_at 395482 PTK2
231156_at 356368 HAO2 209191_at 193491 TUBB6
200789_at 196176 ECH1 218211_s_at 102406 MLPH
219466_s_at 237658 APOA2 235399_at 298079 KLC3
Cell adhesion Cell adhesion
200808_s_at 490415 ZYX 44673_at 31869 SIGLEC1
232059_at --- DSCAML1 211945_s_at 643813 ITGB1
Signal transduction Protein metabolism
216835_s_at 103854 DOK1 200019_s_at 387208 FAU
218065_s_at 501853 TMEM9B 200019_s_at 387208 FAU
227561_at 591469 DDR2 211956_s_at 150580 EIF1
204954_s_at 130988 DYRK1B 208974_x_at 532793 KPNB1
220737_at 368153 RPS6KA6 242819_at 489132 BET1
205204_at 386470 NMB 200838_at 520898 CTSB
240950_s_at 373631 FLJ32658
Transcription regulators
205954_at 26550 RXRG Signal transduction
229279_at 572539 ZNF432 244618_at 514690 GPR61
241556_at 585572 SOX5 208439_s_at 54517 FCN2
242025_at 585572 SOX5 225558_at 434996 GIT2
225416_at 550150 RNF12
239411_at 168677 ZNF496 Cell cylce
229621_x_at 591374 EBF3 203694_s_at 485060 DHX16
232895_s_at 335614 SEC14L2 211921_x_at 459927 PTMA
Protein Metabolism Transcription regulator
202138_x_at 301613 JTV1 234921_at 204449 ZNF470
214986_x_at 438587 PPIL2 200855_at 462323 NCOR1
219189_at 12271 FBXL6 229586_at 59159 CHD9
218367_x_at 8015 USP21 229083_at 96996 HNRPA0
213356_x_at 647869 HNRPA1 
Ion transport 231595_at 439524 TRMU
232494_at 447793 CYP8B1
217588_at 253260 CATSPER2 Others/ Unknown
227560_at 44070 SFXN2 232016_at 584863 KIAA1018
242131_at --- LOC440552
Others/ Unknown 233912_x_at 450105 ELMOD2
210779_x_at 645400 SIP1 225069_at 435767 PCYT1A
211429_s_at 525557 SERPINA1 244481_at 132553 SLC25A24
204574_s_at 591033 MMP19 234496_x_at 302019 NYX
35846_at 724 THRA 211416_x_at 355394 GGTLA4
214505_s_at 435369 FHL1 218625_at 103291 NRN1
211298_s_at 418167 ALB 221505_at 603000 ANP32E
232765_x_at 447544 LOC146429 211600_at --- ---
203900_at --- KIAA0467 221717_at --- ---
211424_x_at --- METTL7A 236699_at 134221 MBNL2
219328_at 495410 DDX31 211628_x_at 453583 FTHP1
229933_at 497642 C1orf74 225841_at 7962 C1orf59
232420_x_at 593896 LOC286260 226097_at 524234 FNDC5
234956_at 270133 LOC93444 233008_at 350378 FLJ12825
235095_at 513285 LOC146439 241735_at --- ---
235402_at 502726 C11orf66 224549_x_at --- ---




                                                                                                                  Section 3 Results : mSSH
78
C. 83 NPC-specific probe sets
Probe Set ID UniGene ID Gene Symbol Probe Set ID UniGene ID Gene Symbol
Immune response Lipid metabolisme
209138_x_at 449585 IGL@ 237494_at 6278 DAK
215121_x_at 449585 IGL@ 212737_at 483873 GM2A
215379_x_at 449585 IGL@ 35820_at 483873 GM2A
213932_x_at 181244 HLA-A 209607_x_at 460587 SULT1A3 
212671_s_at 387679 HLA-DQA1 201190_s_at 429819 PITPNA
208259_x_at 282274 IFNA7 231576_at 29464 ETNK1
200984_s_at 278573 CD59 209619_at 436568 CD74
211430_s_at 36989 F7 
203547_at 631659 CD4 Transcription regulator
206567_s_at 517044 PHF20
Cell adhesion 211939_x_at 591768 BTF3
201015_s_at 514174 JUP 223013_at 581171 TBL1XR1
209879_at 591014 SELPLG 217724_at 530412 SERBP1
201105_at 445351 LGALS1 206283_s_at --- TAL1
205180_s_at 501574 ADAM8 214933_at 501632 CACNA1A
208718_at 528305 DDX17
Cytoskeleton 217840_at 484288 DDX41
215479_at 156967 SEMA6A 203376_at 428147 CDC40
229748_x_at 487562 LOC389833 210290_at 155204 ZNF174
213513_x_at 529303 ARPC2 203183_s_at 79335 SMARCD1
200631_s_at 436687 SET
Signal transduction 219248_at 468254 THUMPD2
221426_s_at 532689 OR3A3
396_f_at 631624 EPOR Others/ Unknown
204731_at 482390 TGFBR3 203040_s_at 82609 HMBS
50965_at 3797 RAB26 210243_s_at 321231 B4GALT3
218669_at 119889 RAP2C 242271_at 164073 SLC26A9
208819_at 642874 RAB8A 204271_s_at 82002 EDNRB
200891_s_at 114033 SSR1 226508_at 529592 PHC3
213603_s_at 517601 RAC2 205554_s_at 476453 DNASE1L3
211551_at 488293 EGFR 202031_s_at 122363 WIPI2
202794_at 32309 INPP1 205597_at 335355 SLC44A4
207801_s_at 442798 RNF10
Protein metabolisme 212643_at 594338 C14orf32
208674_x_at 523145 DDOST 213260_at 599993 ---
209678_s_at 478199 PRKCI 213705_at 592466 ---
201217_x_at 119598 RPL3 215696_s_at 522500 KIAA0310
211073_x_at 119598 RPL3 215963_x_at 575313 LOC642741
212039_x_at 119598 RPL3 217737_x_at 517134 C20orf43
201017_at 522590 EIF1AX 218319_at 7886 PELI1
208829_at 370937 TAPBP 220949_s_at 521213 C7orf49
214224_s_at 118076 PIN4 224581_s_at 213061 ---
200807_s_at 632539 HSPD1 225794_s_at 306083 C22orf32
217885_at 596014 IPO9 227473_at 596164 ---
200768_s_at 516157 MAT2A 229145_at 426296 C10orf104
221519_at 500822 FBXW4 234159_at 651816 ---
200682_s_at 108104 UBE2L3 242906_at 120633 ---
212295_s_at 14846 SLC7A1
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D. 115 common probe sets
Probe Set ID UniGene ID Gene Symbol Probe Set ID UniGene ID Gene Symbol
Lipid metabolism Cytoskeleton
214707_x_at 184720 ALMS1 216187_x_at 20107 KNS2
214594_x_at 216623 ATP8B1 244842_x_at 523370 TUBGCP2
213936_x_at 512690 SFTPB 216993_s_at 390171 COL11A2
Transcription regulation Apotosis/cell cycle
214715_x_at 467236 ZNF160 224372_at 435741 IQWD1 
241993_x_at 431498 FOXP1 224373_s_at 435741 IQWD1 
242311_x_at 113876 WHSC1 215067_x_at 432121 PRDX2
208137_x_at 143951 ZNF611 211040_x_at 386189 GTSE1
217715_x_at 484324 ZNF354A 215628_x_at 483408 PPP2CA
205255_x_at 573153 TCF7 215179_x_at 252820 PGF
211452_x_at 471779 LRRFIP1 Others/ Unknown
220113_x_at 86337 POLR1B 220796_x_at 585896 SLC35E1
203221_at 197320 TLE1 232169_x_at 90443 NDUFS8
234687_x_at 193370 LIMD1 238199_x_at --- LOC440552
244197_x_at 133350 CNOT2 236715_x_at 108049 UACA
226049_at 400431 ERC1 233056_x_at 249600 DLGAP4
232516_x_at 584927 YY1AP1 237475_x_at 648541 SEPP1
231825_x_at 591151 ATF7IP 242195_x_at 326953 NUMBL
238324_at 118964 GATAD2A 217042_at 226007 RDH11
232877_at 463041 RERE 205370_x_at 647640 DBT
214902_x_at 444362 LPP
Signal transduction 233041_x_at 116233 BTBD9
206792_x_at 631628 PDE4C 206169_x_at 592188 ZC3H7B
231992_x_at 645326 LOC493754 207730_x_at 43071 HDGF2
241303_x_at 292075 INPP4B 208246_x_at 610957 ---
215404_x_at 264887 FGFR1 210679_x_at --- ---
243442_x_at 435122 PPAP2A 211713_x_at --- KIAA0101
215373_x_at --- FLJ12151
Protein metabolism 215693_x_at 65234 DDX27
207300_s_at 36989 F7 215978_x_at --- LOC152719
234762_x_at 247460 NLN 216372_at --- ---
225177_at 191179 RAB11FIP1 217446_x_at 554681 ---
238863_x_at 130849 COG8 217679_x_at --- ---
222252_x_at 283739 UBQLN4 217713_x_at 369471 TMEM163
205133_s_at 1197 HSPE1 219206_x_at 505934 TMBIM4
217810_x_at 432674 LARS 220071_x_at 14347 CEP27
200026_at 646587 RPL34 220352_x_at --- ---
201492_s_at 632703 RPL41 221155_x_at 621369 ---
215208_x_at 529631 RPL35A 222207_x_at --- LOC441258
232266_x_at 233552 CDC2L5 223662_x_at 497332 DDX59
200971_s_at 518326 SERP1 224493_x_at 137562 C18orf45
218143_s_at 458917 SCAMP2 224667_x_at 426296 C10orf104
233702_x_at 530053 RABGEF1 226062_x_at 3346 FAM63A
233399_x_at 646770 TMED10 226536_at 388297 NSMCE2
231584_s_at 381178 ---
RNA processing 232215_x_at 631750 PRR11
217834_s_at 571177 SYNCRIP 232455_x_at --- LOC340085
200874_s_at 376064 NOL5A 232469_x_at 591438 C1orf191
209067_s_at 527105 HNRPDL 234020_x_at 468702 COMMD1
233193_x_at 533723 INTS4 234788_x_at 591760 FLJ13611
234981_x_at 192586 CMBL
Ion transport 235327_x_at 591576 UBXD4
241223_x_at 369440 SFXN1 238430_x_at 546510 SLFN5
212383_at 463074 ATP6V0A1 238701_x_at 125166 FLJ45803
242578_x_at 567337 SLC22A3 239139_at 121335 CPNE9
239748_x_at 518750 OCIAD1
Ubiquitin pathway 241686_x_at 542861 ---
215604_x_at 108332 UBE2D2 242377_x_at 443081 THUMPD3
207365_x_at 435667 USP34 243760_at 147563 LOC650794
215600_x_at 288793 FBXW12 244495_x_at 137562 C18orf45
44563_at 437460 WDR79
Immune response 51774_s_at --- LOC222070
241268_x_at 580681 SAMHD1 AFFX-hum_alu_at --- ---
215383_x_at 242458 SPG21 AFFX-M27830_5_at --- ---
201891_s_at 534255 B2M AFFX-r2-Hs28SrRNA-3_at --- ---
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3.3 Discussion
SSH is a PCR-based cDNA subtraction technique.  A key feature of this method
is the simultaneous normalization and subtraction steps.  The normalization step
equalizes the abundance of DNA fragments within the target population, and the
subtraction step excludes sequences that are common to the two populations being
compared.  Specific amplification of genes with SSH has allowed identification of small
molecular differences between closely related biological systems.  However, the
comprehensive characterization and quantitation of subtracted cDNA clones following
SSH is often technically laborious, thus severely limiting its utility.  On the other hand,
profiling methods with oligonucelotide arrays do not provide the flexibility to discern
subtle changes between two biological populations.  The present mSSH strategy
combines the advantages of SSH and Affymetrix oligonucleotide probe arrays to enable
global comparison of subtracted cDNAs without mass cloning and sequencing.
Two specific modifications were made to conventional SSH to allow the
generation of uni-directional cRNA from the subtracted cDNA.  In contrast to
conventional SSH method where the T7-promoter is introduced during the adaptor
ligation step, our protocol incorporated the T7-RNA promoter into the 5’ end of the non-
coding DNA strand during first-strand synthesis (Figure 3.1). This incorporation
enabled the generation of antisense RNA from the subtracted cDNA. Secondly, we have
employed the SP6-promoter as the adaptor sequence in place of the T7-promoter used in
conventional SSH (Figure 3.1). The replacement of T7-promoter by SP6 promoter
sequence as adaptors ensured that only antisense RNA could be synthesized by the
following in vitro transcription using T7 polymerase. Together, these modifications have
overcomed the limitation of incorporating T7-promoter to both coding and non-coding
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cDNA, which would result in a mixed population of RNA following in vitro
transcription.  However, if a mixed population of antisense and sense RNA are
preferred, SP6 polymerase can be used in the following in vitro transcription. Therefore,
our modified SSH methodology is able to generate a single anti-sense RNA population
that can be analyzed with oligonucleotide arrays, with minimal background noise.
Following mSSH, over 90% of the common transcripts between tumour and
normal tissues were subtracted. The remaining probe sets represented the preferentially
expressed transcripts that were specific to cancers, and they were validated by real-time
PCR. This observation illustrates that mSSH retained the major characteristic of
conventional SSH in exhibiting high subtraction efficacy.  More importantly, most of the
probe sets identified following mSSH represented low abundance transcripts (Table 3.3
& 3.4). In conventional gene profiling experiments, these transcripts would have been
registered as not significantly different from the background and therefore excluded
from further analysis (2).  The preferential identification of low abundance transcripts by
mSSH was further confirmed when we compared these transcripts to the SAGE
database and demonstrated that over 70% of the transcripts obtained by mSSH were
indeed classified as low abundant species (Figure 3.4c).
Human HCC, breast carcinoma and NPC are among the most common and
lethal human malignancies.  Few studies have focused on genetic similarities and
differences between these tumour types.  We have employed mSSH in combination with
Affymetrix oligonucleotide arrays to compare the gene expression profiles of these
cancers. For the HCC-specific transcripts, some of the corresponding genes are
associated with pathways related to fatty acid metabolism (APOA2, HAO2, ECH1),
signal transduction (DOK1, DYRK1B), and ion transport (CATSPER2, SFXN2). Several of
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the genes identified, including SERPINA1, ALB, AZGP1, APOA2 and CYP8B1, are
known to be regulated by the liver-specific transcription factor HNF4 (3), while the
transcripts SEC14L2, DDR2 and ZYX are reported to be regulated by p53.  These
findings are consistent with the well-documented role of p53 in liver carcinogenesis (4,
5). Two of the genes identified by mSSH have also been previously reported to be
related to HCC using other methods, for example, SIP1 identified by quantitative RT-
PCR (6), and APOA2 identified by microsatellite DNA studies (7). However, the
identification of these low abundance genes remains sporadic.
For the breast cancer-specific transcripts, several genes related to Cathepsin B
(CTSB) were identified, including ITGB1, FAU and SIGLEC1.  CTSB encodes a lysosomal
cysteine protease which degrades the basement membrane and extracellular matrix.  It
has been reported to play an active role in determining the invasiveness of breast cancer
(8). In addition, genes related to cytoskeletons and adhesion molecules dominated the
list. In contrast, the NPC-specific transcripts gave a prominent immunological
fingerprint and most of them are involved in T cell activation and proliferation. Among
these are CD59, HLA-A, TAL-1, CD-74, EDNRB, and LGALS1. T-cell activation plays an
important role in the pathogenesis of NPC and the tumour microenvironment (9), the
discovery of these genes as NPC-specific give further support to the role of T cell in this
malignancy.  Moreover, a large proportion of these genes are implicated in the NFKB1
pathway, amongst them, CD59, RAC2 and UBE2L3 which are regulated by NFKB;
EDNRB, SMARCD1 and LGALS1 by JUN; MAT2A and EPOR by STAT1; and MAT2A,
RAC2 and HLA-A by SP1.  These various transcription factors are known to contribute
to the transforming potential of the Epstein-Barr virus (EBV), which is a well-
documented etiological factor for NPC (10, 11).  This study has also identified the
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signaling and metabolic pathways that are distinct for each cancer type. For example,
some of the genes identified from the HCC-specific transcripts are associated with
pathways related to fatty acid metabolism, signal transduction, and ion transport while
the NPC-specific signature gives a prominent immunological association. Despite
having heterogeneous changes in gene expression across different tissues, our study
demonstrated the presence of a common pool of 115 genes implicated in the emergence
and progression of these three different types of human cancers. We believe that these
115 consensus genes are crucial in the common process of carcinogenesis. However,
many of the transcripts identified by mSSH represent either unknown genes or genes
with no known function. Nonetheless, we found that genes regulating gene
transcription and RNA processing took the biggest portion of the chart, while genes
regulation protein and lipid metabolism are equally significant in number. Furthermore,
these two groups of genes (transcription regulation and protein metabolism) are also
observed in other gene signatures (HCC, breast cancer and NPC) in our study,
highlighting the importance of changes in pathways relating to them. Identification of
genes that are both selectively expressed and common for human HCC, breast
carcinoma and NPC would prove invaluable in furthering our understanding of the
molecular carcinogenesis processes underlying these tumours and eventually aid in
their clinical prevention, diagnosis and treatment.
An additional advantage of mSSH is that it needs relatively small input (1ug
total RNA) compared to the conventional microarray approach. Using mSSH, small and
treasured samples i.e. endoscopic or needle biopsy can be applied directly to mSSH for
oligonucleotide gene profiling assay.  Further more, heterogeneous biological specimens
would not need to go through physical procurement as in Laser Capture
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Microdissection (12) for the pure population, which often results in low level of RNA,
both qualitative and quantitatively (13).
However, a possible drawback of our method is the exponential (PCR) and linear
(in vitro transcription) amplification inherited in the protocol. Many have since discussed
the distortion caused by these amplification methods, mostly focusing at the 3’ bias of
the amplification process (14). However, a recent study suggests that no great distortion
was seen on either amplification method (15, 16). In our experiments, we were unable to
access the 3’/5’ ratio of GADPH and B-Actin, which used by Affymetrix to check the
3’/5’ conservation, because both genes were absent after going through mSSH.
Nevertheless, genes found by mSSH were of biological relevance and had proven to be
truly cancer-specific, ruling out the possibility of identifying large amount of false
positives.
Recently, new technologies has been developed to give better performance in
terms of speed and sensitivity in the field of gene profiling. Among them, SAGE and
Next-Generation Sequencing (NGS) are able to detect low abundance gene (17-19).
Current NGS platforms including Roche 454’s Genome Sequencer, Illumina’s Solexa and
Applied Biosystems’ SOLiD. Together with SAGE, these NGS gives low background,
high sensitivity and large detection range. Unfortunately, both SAGE and NGS are very
costly, and has low sample throughput though generating vast information per sample
(19). mSSH in the other hand, could detect altered genes that are low abundance, in an
economical and high throughput fashion. Comparing to the conventional SSH, it could
generate great number of libraries and screen then simultaneously. mSSH could
complement the current gene profiling techniques, including SAGE and NGS, to give an
alternative view on the  transcriptome alteration in certain diseases. Besides cancer and
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diseases, mSSH could be use to study any two biological samples that are different in
gene expression, even if these difference are subtle.
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3.4    Conclusion
We have generated a new method to identify low abundance, cancer-specific
genes by combining subtraction and oligonucleotide array. In our study, we have
demonstrated that through mSSH, subtracted cDNA can be amplified using in vitro
transcription to generate unidirectional cRNA, and later hybridized onto the Affymetrix
GeneChip. We showed the strategy to combine subtractive hybridization with
oligonucleotide microarrays, valuating the efficacy of subtraction, assessing the
characteristic of subtraction profile, and validating the biological relevance of the data
obtained. Our results showed that mSSH could effectively eliminate common sequence
between tumor and normal samples, where more than 90% of the housekeeping genes
were eradicated. The shifting of target sequence intensities in the subtracted samples
clearly showed that mSSH preserved the important features of the classical SSH to
normalize sequence abundances while amplifying the signal of low abundance genes. At
the same time, it is able to maintain the background hybridization signal at a low level.
Moreover, transcripts identified by mSSH are cancer-specific and of low abundance, and
they are biologically relevant. We therefore conclude that mSSH is a versatile method
that can massively identify low abundance transcript differentially regulated in cancers,
or in other physiological conditions.
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4.1 Summary
FLJ11029 was identified by mSSH as the highest expressed gene in the common
cancer signature. It is a low abundance, highly cancer-specific, novel transcription
repressor for Major histocompatibility class II (MHCII). We named the gene TROM
(Transcription Repressor of MHCII). TROM was found up-regulated in Hepatocellular
carcinoma (HCC), Breast carcinoma, and Nasopharyngeal carcinoma (NPC). Several
lines of evidence suggest TROM as a potent and biologically relevant repressor for
MHCII, whose repression is often observed in cancers. Expression of endogenous TROM
is inversely correlated with HLA-DRA in cancer cells treated with interferon  (IFN)
and in MHCII-deprived immune cells. Over-expression of TROM in both constitutive
and inducible cell lines resulted in marked reduction of HLA-DRA mRNA levels, while
silencing of TROM lead to the reverse. We found that TROM could regulate the
expression of HLA-DRA by two mechanisms. Firstly, TROM binds to the x1-box of the
HLA-DRA promoter and destabilizes the enhanceosome, by competing against the
regulatory factor X (RFX) and cyclic AMP response element binding protein (CREB).
Secondly, TROM deactivates STAT1, an upstream regulator of MHCII during the
induction of IFN, by enhancing the dephosphorylation of Y701 STAT1. We also show
that TROM is able to degrade STAT1 through the proteosome pathway.
In addition, the repression of TROM on HLA-DRA was projected on human
HCC and breast cancer, where a high level of TROM resulted in low level of HLA-DRA
and consequently a bad prognosis. Furthermore, the repression appears to be dependent
on p53 integrity as shown in breast cancer samples. At the same time, we also observed
the ability of TROM as a strong prognostic marker, as it could predict cancer survival
independently from other clinicopathological factor. In histologically difficult samples,
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the predictive power of TROM even exceeded the conventional marker. TROM could
therefore serve as an important player in carcinogenesis, by regulating MHCII
expression which is known to facilitate immuno-surveillance, and whereby such
impairment often leads to the immuno-escape of the tumor cells.
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4.2 Results
4.2.1 Isolation of a low abundance FLJ11029 transcript preferentially expressed in
cancers
From the mSSH study, we have isolated 115 consensus transcripts that were
found to be up-regulated in three cancer types, HCC, breast cancer and NPC. Among
them, FLJ11029/PRR11 was one of the ten candidate genes from the list (1). FLJ11029 has
to pass the filtering criteria of being up-regulated in over 70% of the sample studied, or
N10. More specifically, FLJ11029 was found up-regulated in 12 samples or 80% of the
samples that we studied.  Real-time PCR validation of these genes revealed that the most
consistent result came from the up-regulation of FLJ11029 in tumour samples.  We again
validated the expression of this gene in three independent in-house human cancer
microarray databases. In these databases, FLJ11029 was found to be up-regulated in
HCC with 1.3 folds; 2.5 folds in Breast cancer; and 2.8 folds in NPC (Figure 4.1a).
Furthermore, FLJ11029 expression alone was able to segregate 41 HCC samples from 31
normal liver samples using principal component analysis (Figure 4.1b). To further
validate the differential expression of FLJ11029 between tumour and normal samples,
RT-PCR analysis on 6 paired liver samples was performed and the result showed that
FLJ11029 was generally expressed higher in HCC samples (Figure 4.1c). Moreover, in a
separate real-time PCR analysis using another 7 pairs of independent liver samples,
FLJ11029 was again shown to be preferentially expressed in cancer samples, exhibiting
an average of 3.7 fold difference (Figure 4.1d). Hence, the above observations clearly
illustrated that the low abundance FLJ11029 gene might have a physiological relevance
in various types of cancer.
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Figure 4.1 Expression of FLJ11029 in human cancers.
a) In three independent microarray databases, FLJ11029 was expressed higher, but still in low abundance.
These databases are HCC, breast cancer and NPC databases respectively. Red, cancer samples; blue, normal
samples. b) Principal component analysis of the HCC microarray database. Using FLJ11029 alone, the liver
samples were being segregated to two distinct dimensions separating tumors from normals. c) RT-PCR
analysis of 6 paired liver samples showed up-regulation of FLJ11029 in cancer samples. d)Real-time PCR
was performed on 7 pairs of independent liver samples, same observation was found where FLJ11029 was
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    Figure 4.2 Location of FLJ11029 on chromosome 17q22.
a) Chromosamal location and orientation of FLJ11029 b)  Orthologous comparison of FLJ11029
across mouse, human and rat genomes.
FLJ11029 (also known as Proline region rich 11, PRR11) is an uncharacterised
gene located on chromosome 17q22 (Figure 4.2a). Conserved syntenic region was found
on the flanking gene locus of FLJ11029 across human 17q22, rat 10q26 and mouse 11C
(Figure 4.2b). NCBI database predicted that sequence for human FLJ11029 was 46055bp
long, with a predicted mRNA of 1317bp. Hence, we decided to employ 3’ and 5’ RACE
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FLJ11029 from both 293T and HepG2 cells. The FLJ11029 full length mRNA was 1464
base pairs long obtained from 11 exons, and consisted of a 1083 base pairs open reading
frame (ORF) (Figure 4.3a). Comparing to the reference sequence in NCBI (Hs.631750,
NM18304.2), the sequence obtained from RACE has an additional 161bp at its 3’ end,
and lacked the first 14 bp listed in the reference sequence. However, the deduced amino
acid sequence remained the same between the two sequences. The deduced amino acid
sequence encoded a 40 KD protein that contained a nuclear localization sequence (NLS)
at its N-terminal; two proline rich regions; a zinc binding domain and a N-myristolation
site near its C-terminal (Figure 4.3b). The same sequence was identified from both 293T
and HepG2 cells. The FLJ11029 protein sequences did not match any known gene on
public databases. However, its zinc binding domain has a 60% homology to that of a
transcription repressor, NFX1 (Figure 4.3c). Interestingly, NFX1 was shown to be a MHC
class II repressor that binds to the x1-box region of the class II promoter (2). This
resemblance of the binding domains of the two proteins infers that FLJ11029 might play
a similar role as that of NFX1 in regulating MHCII transcription.
For the ease of discussion, and as FLJ11029 consistently exhibits the attributes of
a transcription repressor of MHCII genes in the later experiments, we named it
Transcription Repressor Of MHCII, TROM.
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Figure 4.3 Sequence and organisation of TROM.
a) Nucleic acid sequence of TROM. The ORF of the gene starts at position 66 and ends at
nucleotide 1148. b) Organisation of the deduced amino acid sequence corresponding to the ORF.
Note that the protein contains a zinc binding domain, a nuclear localisation signal, two proline
rich regions and a N-myristolation site. c) (i) The structure of NF-X1 type zinc finger, where X can
be any amino acid, while numbers in brackets indicate the number of residues. H=Histidine and
C= Cysteine (ii) Homology alignment of the TROM DNA binding domain to that of NFX1. The
sequences were aligned with the SMART program. C = cysteine, G= glycine, H= Histidine, p=
polar, c= charged, s= small, b= big. The alignment revealed a 60% NFX1.
b
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4.2.2 TROM expression is in reverse correlation with HLA-DRA
In an attempt to delineate the molecular function of TROM, which was classified
as an unknown gene highly expressed in immune cells (3), and out of the resemblance of
its zinc binding domain to that of a transcription repressor for MHCII, we sought after
the relation of TROM with HLA-DRA, a classical class II molecule. CNE2, the class II
inducible human NPC cells, were treated with IFN to increase the expression of HLA-
DRA. Subsequently, the expression levels of both HLA-DRA and TROM mRNA were
accessed by real-time PCR. At 48 and 72 hours after IFN treatment, the level of HLA-
DRA mRNA reached its highest (Figure 4.4a(i)); at the same time point, it was observed
that TROM’s mRNA level decreased to its lowest (Figure 4.4a(ii)). This result showed
that the mRNA transcripts of HLA-DRA and TROM were expressed in the opposite
manner.
Knowing that MHC class II expression is tightly regulated in different tissues, we
performed a RT-PCR screening of the mRNA levels of both genes in a normal human
tissues panel. The results revealed that TROM was relatively higher in the tissues that
expressed lower HLA-DRA, notably the brain and the fetal tissues (Figure 4.4b).
To confirm this observation, we employed the model of monocyte differentiation
to investigate the phenomena. In the differentiation process, surface HLA-DRA
expressed progressively higher along with the differentiation process from monocyte to
macrophages (4). Flow cytometry analysis confirmed the up-regulation of surface HLA-
DRA expression in macrophages compared to monocyte (Figure 4.4c (i)). Interestingly,
TROM mRNA level decreased with the process (Figure 4.4c (ii)); it was relatively lower
(0.5 fold) in macrophages where the HLA-DRA was higher (3 folds), and higher in
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monocytes where HLA-DRA was lower. These results indicated that the expressions of
TROM and HLA-DRA are inversely correlated.
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Figure 4.4 Expression of TROM  is reversely correlated with HLA-DRA.
a) Cells treated with IFN were harvested for real-time PCR analysis, grey =untreated cells, black
= IFN treated cells. Compared to the untreated cells, TROM mRNA was reduced in 48 and 72
hours. In contrast, HLA-DRA was highest in 48 and 72 hours. b) In the RT-PCR using normal
human tissue panel, TROM was expressed highest in brain and fetal tissues where the HLA-DRA
expression was the lowest. c) Monocytes undergoing differentiation were analysed for their
expression for HLA-DRA using flow cytometry (i), while half of the cells were subjected to RNA
isolation and real-time PCR analysis (ii). With the increased expression of HLA-DRA, the TROM
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4.2.3 TROM represses the mRNA expression of HLA-DRA
To understand the mechanism underlying the reverse correlation between
TROM and HLA-DRA expressions, TROM was cloned into the expression vector
pcDNA 3.1 fused with V5 and histidine tags at its C-terminal. Cells were transiently
transfected with the expression vectors and analysed for the mRNA level of both TROM
and HLA-DRA, using multiplex PCR. It was observed that over-expression of TROM in
Raji, a human B-cell line that constitutively expresses HLA-DRA, led to a marked
decrease of HLA-DRA mRNA by two folds and above. To correlate this repression effect
of TROM on HLA-DRA in the three cancer libraries from which we isolated TROM,
NPC line CNE2, breast cancer line MCF7, and HCC line PLC/PRF/5, were subjected to
similar over-expression of TROM. It was observed that significant HLA-DRA repression
was replicated in all three cell lines, with the reduction ranging from two to five folds,
when compared to the empty vector control (Figure 4.5a (i)). To further investigate the
repressive ability of TROM on HLA-DRA, these MHCII inducible lines were treated
with IFN for a 24 hours before transfection. In all three cell lines, induction of IFN
resulted in increased level of HLA-DRA (Figure 4.5 b(i)). Concurrently, the over-
expression of TROM caused a significant decrease in HLA-DRA expression in these
IFN treated cells. The mRNA level of HLA-DRA was reduced by above two folds
compared to the empty vector control, similar to the level of its original expression
without IFN treatment (Figure 4.5 a(i)). The level of TROM mRNA after transfection is
shown in Figure 4.5 a (ii) and b(ii). Hence, above results indicated that the reverse
correlation of TROM and HLA-DRA observed earlier might be due to the repression
effect of TROM on the transcription of HLA-DRA both in constitutive and inducible
systems.
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Figure 4.5 Over-expression of TROM represses HLA-DRA
a) Transient transfection of TROM repressed the expression of HLA-DRA. Real-time PCR analysis of
(i)HLA-DRA  and (ii) TROM were performed for the TROM- and empty vector (control)-transfected
cells. b) Transient transfection of TROM in cells treated with IFN for 24h. Real-time PCR analysis of (i)
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4.2.4 Silencing of TROM releases the repression of HLA-DRA
To further strengthen the observation that TROM was able to efficiently repress
the expression of HLA-DRA, we sought to determine whether disruption of endogenous
TROM was sufficient to elicit transcription of HLA-DRA. We therefore investigated the
level of HLA-DRA in cells depleted of TROM by siRNA.  Realtime-PCR showed that
silencing of TROM resulted in an increased level of HLA-DRA mRNA in all CNE2,
MCF7, and PLC/PRF/5 (Figure 4.6a). In CNE2 cells, the induction of HLA-DRA due to
the silencing of TROM was three folds higher at 24 hours and five folds at 48hrs, as
compared to the control (Figure 4.6a(i)). In MCF7 and PLC/PRF/5 cells (Figure 46a(ii)
and (iii)), the augmentations of HLA-DRA transcription were around 2.5 folds for both
time points, a significant change comparable to the effect of IFN treatment to the native
cells (4.5b(ii)). These results confirmed the physiological role of TROM in repressing
HLA-DRA expression. To test the off target effect of the siRNA, the level of NFX1 and
MHCI was analysed (Figure 4.6b) . The result showed that the depletion of TROM
specifically enhanced the level MHCII and not MHCI.
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Figure 4.6 Silencing of endogenous TROM enhances the transcription of HLA-DRA.
Real-time PCR was performed on i) CNE2 ii) MCF7 and iii) PLC/PRF/5 that were treated with
RNAi for TROM or negative control, for the indicated times. Endogenous TROM was depleted
after 24 hours of RNAi treatment, while the level of HLA-DRA was augmented at the same time.
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4.2.5  TROM silences HLA-DRA transcription by promoter binding
The repression of MHCII is a result of the interactions between activators and
repressors that form a complex circuitry. Having established the ability of TROM to
suppress endogenous MHCII, we next investigated the mechanism of how the
phenomenon could occur. As previously mentioned, MHCII genes are highly regulated
at the transcriptional level by three conserved elements (x, y and s boxes) at its
promoter. We therefore cloned HLA-Luc, a pGL3 luciferase reporter plasmid fused with
the proximal promoter of HLA-DRA starting from region –133 to +30 relative to its
transcription start site spanning all these regions (Figure 4.7a). In the inducible cell line
CNE2, HLA-Luc alone gave a low activity and made the cell line unsuitable for the
luciferase assay for this particular experiment. We therefore used Raji and 293T cells to
perform the experiments. Raji and 293T cells were transfected with HLA-luc, along with
expression plasmid for TROM. Transfection of TROM led to a decreased level of HLA-
DRA expression, in a dose-dependent manner in both cell lines (Figure 4.7b). The result
indicated that TROM repressed the expression of HLA-DRA by acting directly on its
promoter region containing the conserved transcriptional machinery.
To address the mechanism by which TROM represses HLA-DRA expression via
its promoter, we performed Electro Mobility Shift Assay (EMSA) using the same
promoter region as used in the luciferase experiment. TROM-His fusion protein was
purified from CNE2 cells after transient transfection with the TROM expression
plasmid, and was used in the EMSA. The shifted band in lane 2 to 6 showed that
purified TROM was bound to the HLA-DRA promoter (Figure 4.7c(i)). Interestingly, the
shifted probe-protein complex was only depleted by the addition of cold x1-box
competitors (lane 3 and 6), and not by cold S-box (lane 4), nor Y-box competitor (lane 5).
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We repeated EMSA using an increased amount of competitors and the same observation
was obtained, where x-box cold competitors (Figure 4.7c (ii) lane 5 and 6) were able to
deplete the shifted bands and not S (lane 3 and 4) nor Y-box (lane 7 and 8) cold
competitors. The results indicated that TROM bound specifically to the x1-box region of
the HLA-DRA promoter.
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Figure 4.7 Binding of TROM to HLA-DRA promoter
a) Promoter architecture of HLA-DRA. b)  Luciferase activity of HLA-Luc was represses by the expression
of TROM. c) EMSA using the x1-box and TROM.  The binding of TROM to the probe was competed away
using x1-box cold competitor.
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4.2.6 The binding of TROM to HLA-DRA promoter destabilizes the enhanceosome
complex.
Figure 4.8 TROM affects the binding of RFX and CREB to the HLA-DRA promoter
Promoter pull down assay was performed using the HLA-DRA promoter from –133 to +30
relative to the transcription start site. The pulled down proteins was subsequently eluted in SDS
PAGE and detected with the antibodies for the enhanceosome members.  Binding of RFX to the
promoter was affected while binding of CREB to the promoter was abolished, in the presence of
TROM. The amount of  input proteins were shown in the western blot using total cell lysate.
HLA-DRA promoter is bound by a few synergistic activators, RFX, CREB and
NFY, to form a stereospecific enhanceosome, and the binding position of these factors
are critical for efficient activation of the promoter. Since TROM was shown to bind to the
x1-box region, which is also the binding site of RFX, and in close proximity with the
region where CREB binds (x2-box), we hypothesized that TROM might affect the
binding affinity of these activators to the promoter. To envisage our hypothesis, we
performed promoter pull down assay with the HLA-DRA promoter sequence as probe,
to pull down the bound proteins from the whole cell lysates. CNE2 cells treated with or
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without IFN, and transfected with TROM expression plasmid or empty vector control,
were used for the assay. The results showed that TROM was recruited to the HLA-DRA
promoter, and two of the known enhanceosome proteins, RFX and CREB, were affected
in their binding affinity to the promoter in the presence of TROM (Figure 4.8).
Comparing to the empty vector transfected cells, we observed that the binding of RFX
was decreased by TROM, and the binding of CREB was almost abolished. However, the
binding of NFY, the other member of the enhanceosome, was not affected. Reduced
levels of RFX and CREB pulled down by the promoter in the presence of TROM
indicated that TROM’s binding to the HLA-DRA promoter disrupted the binding of
these activators, and hence the enhanceosome complex.
To further investigate this mechanism, we examined the effect of in vivo binding
of TROM to the promoter using chromatin immunoprecipitation (ChIP) assay. Using
real-time PCR to quantitate the amount of chromatin precipitated by the respected
antibodies, we found that V5-tagged TROM efficiently immuno-precipitated the HLA-
DRA promoter sequences (Figure 4.9). In agreement with the promoter pull down assay,
RFX antibody immno-precipitated less chromatin in the TROM transfected cells when
compared to the control. However, although the difference was small, it was statistically
significant. In contrast, CREB antibody precipitated the basal level of chromatin in the
TROM transfected cells. Figure 4.9a shows the result of the PCR done with the
precipitated chromatin while Figure 4.9b shows the result of real-time PCR. Together,
these results showed that TROM’s binding to the promoter correlated with the reduction
of RFX-promoter interaction, and it prevented the immuno-precipitation of the HLA
promoter by CREB. Therefore, TROM’s binding is enough to destabilize the formation of
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enhanceosome on the promoter, leading to the down-regulaion of HLA-DRA gene
expression.
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Figure 4.9 Chromatin Immunoprecipitation (ChIP) analysis.
Chromatin was prepared from CNE2 cells that were untreated or treated with IFN, and
transfected or not transfected with TROM. anti V5, anti RFX and anti CREB antibodies were used
to precipitate the HLA-DRA promoter. a) RT-PCR of immunoprecipitated promoter b) The real-
time PCR results are presented in fold change comparing relative promoter association of the
immunoprecipitated protein to that of the untreated and untransfected cells. V5-tagged TROM
precipitated a high amount of HLA-DRA promoter, while the precipitated promoter by RFX was
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4.2.7 TROM degrades STAT1 under IFN induction
In our previous experiments, IFN induced cells showed marked reduction in
HLA-DRA transcript level after the transfection of TROM. MHCII expression is
inducible by IFN under the signal transduction pathway which involves JAK1, JAK2,
and STAT1.  We therefore investigated whether under IFN  treatment, TROM could
regulate MHCII expression via these signalling molecules. Confocal microscopy analysis
of CNE2 cells showed that after 24 hours of IFN treatment, the protein levels for both
JAK1 and JAK2 were not changed. However, cells expressing TROM showed no staining
for STAT1 (Figure 4.10a). To examine the phenomenon, time-dependent analysis after
IFN treatment was performed. The results showed that at time 0 and 30 minutes after
IFN treatment, STAT1 and TROM co-localized in the cytoplasm of the cell (Figure
4.10b).   After 8 hours of induction, while adjacent cells have their STAT1 translocated
into the nucleus, cells that expressed TROM retained STAT1 outside the nucleus.
Interestingly, TROM was found to express in both cytoplasm and nucleus at this time
point. At 24 hours, STAT1 staining in the cells expressing TROM was abolished while
TROM’s staining remained in both compartments. We therefore hypothesized that the
STAT1 protein is being barred from entering the nucleus upon IFN treatment, and
subsequently degraded in the presence of TROM. To test this hypothesis, we sought to
invert the degradation of STAT1 using different degradation pathway inhibitors. As
shown in Figure 4.10c, both proteosome inhibitors MG132 and lactacystin were able to
rescue the TROM mediated degradation of STAT1. However, no lysosome inhibitors
(chloroquine and ammonium chloride), nor calpain inhibitor ALLN, could reverse the
degradation. These results showed that the disappearance of STAT1 staining was due to
a TROM-mediated proteosomal degradation pathway.
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Figure 4.10 TROM degrades STAT1 via proteosomal pathway.
a) Confocal analysis of the components in JAK/STAT  pathways. CNE2 cells transfected with
TROM for 48h were fixed and stained with the antibodies for JAK1, JAK2 and STAT1. Individual
transfected cells were indicated with an arrow. In the last panel, TROM-transfected cell showed
no staining for STAT1. b) Cells were treated with IFN and fixed at a indicated time points and
stained for  STAT1 and TROM. Cytoplasmic retention of STAT1 was observed starting 8h and it
was subsequently degraded at 24h. c) Cells transfected with TROM for 48h were treated with
IFN for another 24h. Cells were treated with proteosome, calpain and lysosome inhibitors 16h
before fixation.  Individually transfected cells indicated with arrows showed that the STAT1
staining was restored only after treatment of proteosome inhibitors.
Figure 4.10 c
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Furthermore, when the half life of STAT1 was analysed with cells treated with
cycloheximide and IFN (Figure 4.10d), it was found that in STAT1 degraded faster in
the presence of TROM. Under IFN treatment, the half life of STAT1 was at 8h, however,
when the cells were over-expressed with TROM, the half life of STAT1 is now at 1h,
indicating that TROM mediates degradation of STAT1.
Figure 4.10d TROM degrades STAT1 via proteosomal pathway.
d) Half life analysis of STAT1. Cells were transfected pTROM or pControl and then treated with
IFN and cycloheximide (CHX) for the indicated timepoints. Half life of STAT1 was determined
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4.2.8 TROM impairs phosphorylation of Y701 p-STAT1
Tyr701 phosphorylation is essential for the dimerization and nuclear
translocation of STAT1, while Ser727 enhances the transactivation activity of STAT1. To
investigate, CNE2 cells were treated with IFN at the indicated timepoints after TROM
or control vector transfections. Western blot analysis was then performed with
antibodies probing the different specific residues of phosphorylated STAT1 (p-STAT1)
(Figure 4.11a). The results showed that phosphorylation of tyrosine residue (Tyr701) of
STAT1 was impaired in the presence of TROM, compared to the serine residue (Ser727)
of STAT1, and total STAT1. Together, the blot also showed the decreased level of HLA-
DR affected by TROM. These results indicated that TROM preferentially impaired the
phosphorylation of Y701 p-STAT1 which is needed for the translocation of STAT1 into
the nucleus. To investigate the loss of Y701 p-STAT1, we next examined the possibility
of TROM mediating the ubiquitination of Y701 p-STAT1. CNE2 cells were transfected
with histidine-tagged ubiquitin and expression plasmid for TROM. As shown in Figure
4.11b, p-STAT1 Y701 was ubiquitinated following the treatment of IFN. In addition, the
presence of TROM enhances the ubiquitination of p-STAT1. Together, the results
indicated that TROM could mediate the ubiquitination of Y701 and caused the
degradation of this STAT population, which is needed for the translocation of STAT1
into the nucleus.
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Figure 4.11 Dephosphorylation of Y701 p-STAT1  by TROM.
a) Western blot analysis of TROM-transfected or untransfected cells under IFN treatment. Cells
were harvested at the indicated time points and were subjected to SDS PAGE analysis. The blot
was probe with STAT1 antibody, and antibodies specifically targeting Tyr701 or Ser727 residue of
phosphorylated STAT1. Note that Tyr701-p-STAT1 is being markedly degraded in the presence
of TROM.  b) ) Ubiquitin assay showed that  with the IFN treatment, Tyr701-p-STAT1 was being
ubiquitinated, and the ubiquitination increased with the presence of TROM.
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4.2.9 TROM acts as a strong prognostic marker
TROM was initially isolated as an up-regulated low abundance gene in HCC,
Breast cancer, and NPC. After we established its function as a transcription repressor of
MHCII, we explored the possibility of TROM being used as a prognostic marker in
cancer. We accessed large independent microarray cohorts for this analysis. Two of the
datasets are publicly available; they are HCC database from Wong et al (5), and the
Uppsala breast cancer database (6). The lung cancer database was developed in-house
and it is an unpublished database served for other research purposes conducted in our
laboratory.
By grouping the cancer samples according to their disease stages, we found that
the expression of TROM showed a strong association with cancer staging (Figure 4.12a).
It was expressed progressively higher when the malignancies advanced. In HCC, the
level of TROM was highest in stage III and stage IV tumour, and was lowest in stage I
tumour. The same observation was found in Breast cancer database, where TROM was
lowest in stage I tumour and augmented progressively in stage II and stage III cancer.
Lung cancer was categorized by subtype rather than staging, with squamous cell
carcinoma having the worst outcome and adeno-carcinoma a relatively better prognosis.
In concordance with our previous observation, squamous cell carcinoma displayed a
significant higher expression of TROM compared to adenocarcinoma, suggesting that
advanced stages of lung, breast and liver cancer correlated with higher expression of
TROM.
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 Figure 4.12 TROM as a strong prognosis factor
a) TROM was associated with clinical staging and cancer subtype that showed elevated TROM in
advanced stage of disease. Signal intensity of TROM was depicted in i) 78 HCC microarray
database (8 was not included in this analysis for the cancer staging was unknown) ii) 204 Breast
cancer database and iii) 185 Lung cancer database. b) Comparison of survival curve of TROM-
high and TROM-low groups in i) HCC database and ii) Breast cancer database. c) TROM could
predict survival in grade II breast cancer (i) The survival curve of breast cancer database
grouping by cancer stage  (ii) The percentage of TROM-high and TROM-low patients in each
cancer stage (iii) Survival curve of TROM-high and TROM-low groups in Grade II patients.
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Grade (%) I I I I I I
TROM Low 9 1 6 8 2 1
TROM High 9 3 2 7 9
Total No. 5 7 105 4 2
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P=0.007








































































c (i) Breast cancer














































(iii) Grade II breast cancer
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We next examined the ability of TROM to predict survival. HCC database was
stratified with the intensity of TROM, by arbitrarily assigning samples with TROM
greater than 250 (mean intensity) as TROM-high, and those lesser than 250 as TROM-
low. A survival analysis was then performed using these criterias (Figure 4.12b(i)). We
found that the level of TROM exerted a significant negative effect on survival. The curve
between TROM-high and TROM-low group has a vast different of 40% (p=0.001). In
breast cancer, TROM alone was also a strong indicator for survival (Fig 4.12b(ii))
(p=0.001).
Interestingly, cancer staging is also a strong predictor for breast cancer (p=0.002)
(Figure 4.12c(i)). We therefore decided to stratify each stage of cancers to TROM-high
and TROM-low according to the intensity of TROM (μ=125), and we found that majority
(90%) of grade I cancers (n=57) were TROM-low, whereas 80% of grade III cancer (n=42)
were TROM-high. The results again suggested a role of TROM in disease progression
(Figure 4.12c(ii)). Grade II cancer (n=105) is the biggest group of three, it has a relatively
mixed population of TROM and it formed a medial curve in the survival analysis. Grade
II breast carcinoma is the most frequently presented stage at detection and the staging is
not helpful for clinical decision due to the mixed recurrent and prognosis outcome (7).
To test if TROM could be a better prognosis marker for this particular stage of breast
cancer, we used the intensity of TROM to analyze the grade II samples. Interestingly, it
was observed that in grade II cancer, TROM-high individuals suffered a poorer survival
when compared to TROM-low individuals (Figure 4.12c(iii)), indicating TROM could act
as a stronger prognostic marker in various type of cancer than cancer staging, and it
could help to further refine the staging of breast cancer which then could help to
provide better treatment options.
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4.2.10 The relation of TROM and HLA-DRA in cancer
Having established the inverse relation of TROM and HLA-DRA in vitro, we
would like to investigate their association under physiological condition. Recurrent rate
of HCC is high, making it one of the most critical prognosis factors. We segregated the
78 HCC samples according to their recurrence status, and found that the expression of
TROM was significantly higher in samples with history of recurrence. Interestingly, the
level of HLA-DRA was expressed inversely with TROM; where its level was higher in
non-recurrence samples, and lower in recurrence samples (Figure 4.13a). We next
segregated the samples according to trom, and found that hla-dra was still expressed
inversely with trom. These results, together with the observation that TROM could
repress the expression of HLA-DRA in cancer, suggest a biological meaningful function
of TROM in promoting cancer progression and recurrence, possibly through tumour
evasion. Furthermore, these are the same samples that were used for the survival
analysis (Figure 4.12b) where we had showed that TROM high group is having less
preferable prognosis.
Since in HCC, HLA-DRA was in reverse correlation with TROM, we therefore
predicted the same association of TROM and HLA-DRA in breast cancer. However,
HLA-DRA was not in any relation with TROM in the total population of breast cancer
samples according to cancer staging (the most prominent pathological factor), nor in the
TROM-high/low groups. To further investigate this phenomenon, we examined the
association of the two genes under ER and p53 subtypes, the two prognostic markers
where p53 mutated samples and ER negative samples have been associated with
aggressive phenotypes (8). Surprisingly, it was observed that TROM and HLA-DRA
were inversely correlated in p53-mutated group, and not in samples having wild type
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p53 (Figure 4.13b). We also observed similar correlation in ER negative group (Figure
4.13c), but it was not statistically significant. Another striking observation from the
analysis was that in p53 mutated samples, 78% of them were TROM-high, while only
24% of the p53 wild type samples were TROM-high. The elevated level of TROM in
these groups of cancer in combination with a p53 mutation status might explain their
aggressiveness due to a low level of HLA-DRA.
However, when we performed similar analysis according to the level of HLA-
DRA in both HCC and breast cancer cohorts, we found that although HLA-high group
has a better prognosis, the difference between HLA-high and low group was not
significant, even under the ER and p53 subgroups (Figure 4.13d). These results indicated
that TROM is a better prognostic factor than HLA-DRA in cancer, and that TROM might
harbour more functions than regulating HLA-DRA in carcinogenesis.
TROM
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Figure 4.13 HLA-DRA repression by TROM in human cancers.
a) The intensities of TROM and HLA-DRA were examined in HCC dataset by (i) sub-grouping
the dataset into individuals with history of recurrence (R), or non-recurrence (NR). (ii) the HCC
dataset was sub-grouped into TROM-high and TROM-low groups, and the signal intensities of
TROM and HLA-DRA were shown. Both data showed the repression of HLA-DRA by TROM in
HCC b) and c) showed the breast cancer dataset that was further grouped into different subtypes.
b) (i) In p53 wild type  individuals, no correlation was observed between TROM and HLA-DRA
(ii) in p53 mutated individuals, a clear reversed correlation was observed. c) (i) In ER positive
individual, the correlation was lost while it was observed again in  (ii) ER negative group, but it
was not statistically significant., indicating the repression was shown only in p53 mutated group.
d) Survival curve analysis of HCC and breast cancer data sets stratified with the level of HLA-
DRA. The result showed that although patients with higher HLA-DRA had better prognosis
outcome, HLA-DRA alone is not a suitable prognosis marker.
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4.3 Discussion
Transcriptional regulation of MHC class II molecules is unique. It involves a
group of proteins that are regulated differently in a cell-type dependent manner, yet act
synergistically on highly conserved promoter. These proteins, namely RFX, CREB, and
NFY, drive the basal transcription machinery of MHCII (9). Over the past decades much
advancement have been made on the functions and cooperative mechanisms of these
enhancers, while little is known about the silencing mechanisms used to shut down the
transcription of MHCII, a prominent features in many cancers. To date, there are three
known repressors for the MHCII, namely NFX1, YY1 and Oct1 (10), while their silencing
mechanism are still not well illuminated. It was observed that over expression of NFX1
repressed the transcription of MHCII, and it binds to x1-box the HLA-DRA promoter (2).
As for YY1 and Oct1, the two proteins form a repressosome in Rb negative cells, that
prevents the binding of the activator NFY to the HLA-DRA promoter (11).
    Here, we report a novel transcription repressor of MHCII called TROM. Before
our study, TROM or clone FLJ11029 was an uncharacterized gene. To date, no literature
was found on the characterization of the gene in any aspect. However, FLJ11029 (TROM)
was found in the databases of four extensive studies, as an uncharacterized gene related
to the cell cycle progression and a highly immune specific gene with no known function.
In the first study, Weinmann et al developed a method to identify human
transcription factor targets by coupling chromatin immunoprecipiation (ChIP) with CpG
island microarray (12). In the study, the group employed E2F1 and E2F4 antibody to
identify E2F target genes. FLJ11029 was found as a novel E2F target, with a consensus
E2F binding site located 300bp upstream of its transcriptional start site (Figure 4.14a).  In
the second study, Whitfield et al conducted a study to examine cell cycle related genes
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(13). HeLa cells were synchronised using three different methods, double thymidine
block, thymidine-nocodazole block, and mitotic shake off, to identify genes that
periodically expressed along cell cycle progression. In the gene list annotating genes
highly expressed in G2 phase, FLJ11029 was listed together with HDAC3, TUBB2,
CENPF, and many other G2 phase specific genes. In the last two studies, although the
experiments implicate the role of FLJ11029 in cell cycle control, there was no direct
evidence of the gene being involved in tumorigenesis, and its function remains
unknown. In the third study, Krasnoselsky et al performed an extensive microarray
profiling on neuroblastoma tumours, comparing genes associated with each tumour
stage, and their relations to MYCN amplification (14). It was shown that FLJ11029 was
one of the genes found highly up-regulated in stage 4 tumours without MYCN
amplification, and the authors also pointed out that this group of genes were cell cycle
related. Lastly, in an attempt to identify immune related genes, Abbas at el established a
collection of genes that showed specific expression in immune cells, which was called
Immune Response In Silico (IRIS) (3). The genes listed in IRIS were relatively highly
expressed in immune cells when compared to other major organs. Under IRIS, FLJ11029
was highlighted as a highly specific gene in activated memory T cell, and in other T-cell
subsets (Figure 4.14b), implicating a prominent role of the gene in regulating immune
response.
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Figure 4.14 Literature review of FLJ11029(TROM)
The novel gene FLJ11029 was found in a few databases profiling different physiological
pathways. One of them is depicted in a) ChIP on chip assaying new E2F targets, where
FLJ11029 was listed as one of the new targets; and b) FLJ11029 was highlited as a novel gene
with strong association with immune cell types, especially T cells. However, none of the
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 In this study, we characterized FLJ11029 and named it TROM for Transcription
Repressor of MHCII. TROM is a low abundance gene highly expressed in cancer found
by the modified suppression subtractive hybridization (mSSH) method discussed in the
earlier chapter. The specificity of TROM’s expression in cancer was confirmed by
independent microarrays and real-time PCR. Sharing a 60% homology with the DNA
binding domain to that of a MHCII repressor, NFX1, we found that TROM could
drastically reduce the transcription activity of HLA-DRA via its promoter when over-
expressed.
Endogenously, the expression of TROM was constantly in reverse correlation
with the expression of HLA-DRA. This observation was found in IFN treated cells, in
human tissues deprived of MHCII expression, and in immune cells expressing different
levels of HLA-DRA. When over-expressed, TROM effectively silences the transcription
of HLA-DRA. In Raji cells, where MHCII molecules are constitutively expressed, HLA-
DRA expression was down regulated to one-third of its original level by TROM. This
repression was equally reproducible and effective in MHCII inducible cell lines (CNE2,
MCF7 and PLC/PRF/5), even in the presence of IFN.  In a physiological situation, our
results implicate that without IFN, TROM acts to prevent MHCII transcription in the
MHCII deprived cells, while in the presence of IFN, TROM could turn off the immune
response triggered by IFN, which then direct towards impaired antimicrobial and
antitumor immune response (15). This hypothesis was proven in the silencing
experiment, which endogenous TROM in inducible cell lines were depleted by siRNA.
Upon the depletion of TROM, the level of HLA-DRA was augmented, implicating the
release of repression by TROM in these cell lines.
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After much investigation, we found that the repression of HLA-DRA by TROM
was at least due to two mechanisms. Firstly, the repressive action of TROM occurs via
the conserved proximal region of the HLA-DRA promoter. TROM was shown to be able
to reduce transcription activity directly from the reporter plasmid fused with the
proximal promoter of HLA-DRA. Furthermore, TROM was tightly associated with the
HLA-DRA promoter in both EMSA, promoter pull down assays, and ChIP assays.
Results from the experiments revealed that TROM bound specifically to the x1-box of
the HLA-DRA promoter but not S or Y box. Interestingly, TROM’s binding led only to a
partial disruption of RFX on the same promoter region. However, the binding of CREB
to the neighbouring x2-box was almost completely abolished. This observation is
intriguing, since RFX binds to x1-box while CREB sits on the x2-box, RFX’s binding to
the promoter would be affected more than CREB. A possible explanation could be that
TROM disrupts the binding of CREB to the promoter via steric hindrance, since x2-box
is adjacent to x1-box. Also, the partial interference of RFX’s binding by TROM could be
enough to inhibit CREB’s occupation on the promoter, as this occupation is highly
dependent on RFX (16). Notably, the promoter occupation of NFY was not affected in
the presence of TROM, ruling out the possibility of TROM being a member of the
repressosome consisting of YY1 and Oct1, as the repressosome sits on the Y box and
inhibits the binding of NFY to the promoter (11).
Therefore, one mechanism by which TROM negatively regulates the expression
of HLA-DRA, is to hinder the binding, though to a different extent, of two components
of the enhanceosome, transcription activators RFX and CREB on the promoter. This in
turn could prevent the association of the complex to other key non-DNA binding co-
Section 3 Results : TROM
131
activators of the transcription machinery such as CIITA, hence leading to the down-
regulation of MHC class II genes (17)  (Figure 4.15).
Figure 4.15 The proposed model of enhanceosome destabilization by TROM
We proposed a model of how TROM destabilized the enhanceosome formation on the HLA-DRA
promoter. In scenario (i), without the presence of TROM, the transcription of HLA-DRA was
activated when the enhanceosome assembled on the promoter and CIITA initiated the basal
transcriptional machinery for the HLA-DRA. However, in scenario (ii) where TROM competes
with RFX for x1-box, it disrupts the binding of CREB onto the x2-box due to its heavy association
with RFX. Now without CREB binding and with less RFX binding, CIITA is unable to form the

















Section 3 Results : TROM
132
 IFN is a potent regulator of MHCII transcription (18). Upon stimulation, a
sequential recruitment of IFNR1/2, JAK1, JAK2 is orchestrated, to allow the
phosphorylation of STAT1, which in turn translocates to the nucleus and induces the
IFN responsive genes. Many of these genes contribute to the final transcription of
MHCII genes.  Therefore, although in an indirect manner, STAT1 translocation is crucial
to the transcription of MHCII. The translocation ability of STAT1 depends on the
phosphorylation of its tyrosine residue on position 701. Once phosphorylated at Y701,
STAT1 dimerizes and translocates into the nucleus. Its transactivating function is then
enhanced with the phosphorylation of S727 (19, 20).
Our confocal analysis showed a cytoplasmic retention of STAT1 by TROM.
Furthermore, after 24 hours IFN treatment, we observed that cells which have been
transfected with TROM showed a dramatic absence of STAT1. We hypothesized that the
presence of TROM could be inducing the degradation of STAT1 protein upon IFN
treatment. Confocal analysis showed that when cells were treated with MG132 and
lactacystin, two inhibitors of the proteosomal degradation pathway, the degradation of
STAT1 mediated by TROM was rescued. However, further investigation is needed to
illustrate the exact mechanism of TROM’s involvement in STAT1 degradation.
Interestingly, before the absence of STAT1 staining was observed at 24 hours
after IFN treatment, it was observed that STAT1 was retained at the cytoplasm. STAT1
translocation depends on the proper phosphorylation of its Y701 residue, an impairment
of the phosphorylation at this site would inhibit the translocation. Indeed, western blot
analysis showed that p-STAT1 Y701 is preferentially dephosphorylated in the presence
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of TROM. Furthermore, we showed that TROM enhanced the degradation of Y701
phosphorylated STAT1 through the ubiquitin pathway. However, whether TROM
directly degrades p-STAT1 Y701, remains to be investigated.
Therefore, the second mechanism by which TROM represses the transcription of
MHCII is through inactivation of the IFN signalling pathway by the degradation of
STAT1 and Y701 p-STAT1. A model summarizing the above observation is shown in
Figure 4.15. It is interesting to observe such a repressive function of TROM and one
could argue about the redundancy of such dual functions working on the same
pathway. However the expression of MHC Class II genes are regulated by quite a
complex interplay of factors upon stimulation with IFN. Also, IFN treatment results in
immediate transclocation of STAT1 to the nucleus (21), while TROM mediated
degradation of STAT1 was observed only after 24 hour of IFN induction. Hence, the
mechanism might not be able to inhibit the initial wave of MHCII transcription. We
therefore propose that TROM’s degradation of STAT1 might act as a secondary
mechanism to negatively regulate the prolonged MHCII transcription, whereas the
enhanceosome complex disruption at the promoter via direct binding is the initial route
for the regulation of MHC Class II genes.
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Figure 4.16 TROM impairs phosphorylation of STAT1 and degrade STAT1 via proteosomal
pathway.
The model on how TROM indirectly represses transcription of HLA-DRA via degradation of
STAT1. Situation (a) resembling normal cells where there is very little or no presence of TROM,
STAT1 retained in the cytoplasm without IFN induction. Upon IFN induction, STAT1 was
phosphorylated, dimerized and translocated into the nucleus for the activation of down stream
target genes, which are needed for the transcription of HLA-DRA. Situation (b) resembling the
tumour cells where TROM is highly expressed, both TROM and STAT1 retained in the cytoplasm
when there is no IFN induction. During this time, there is no degradation of STAT1. However,
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Immunoediting of cancer involves silencing of MHC II genes and down
regulation of their expressions. MHC and IFN pathways are both targets for tumor
evasion (22-25).  In recent years, accumulated research data have revealed more
evidences for the hypothesis. Hla-dra down-regulation were observed in HCC using
microarray analysis (26); positive correlations between HLA-DR expression and
prognosis were found in gastric and colorectal cancer (27, 28); HLA-DR expression is in
in negative relation with tumour grade, but positive with prognosis in breast cancer (29,
30). Low expression of HLA-DR helps to sculpt tumour formation in an immuno-
competence individual. TROM was initially isolated from subtraction libraries selecting
for low-abundance but tumor-specific genes, preferentially expressed in cancer biopsies.
In order to further test the hypothesis that TROM could play a role in cancer
evasion, we decided to look at the relationship between TROM expression and the
different stages of cancer. After interrogation of large independent microarray cohorts of
HCC, breast cancer and lung cancer, we observed a low but consistent up-regulation of
TROM in all the cancer samples across three cancer types (HCC, breast cancer and NPC)
compared to normals. Moreover, in HCC and breast cancer, there was a significant
correlation between TROM expression level and survival rate. Patients with high level of
TROM in both cancers had a much poorer prognosis compare to those with low level of
TROM. We therefore propose that TROM is consistently over expressed in tumor cells to
suppress the expression of MHCII molecules, which leads to the immune escape of these
cells, that eventually adapt and triggers immuno-tolerence to allow tumor formation
and progression. Tumour cells expressed Tumour Antigens (TA) which are not found on
normal tissues. These antigen is presented via both MHC class I and class II molecules,
and activate both CD4+ and CD8+ T cells, Specifically for MHC class II, the TAs are
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gp100, MAGE-1,MAGE-3, Tyrosinase and NY-ESO-1 (31) . By suppressing the
expression of MHCII, these TA could not be presented to the CD4+ T cells, which in
turns would lead to the inactivation of the cytolytic pathway. Hence, by over-expressing
TROM in cancer cells, the immune surveillance system is suppressed.
Furthermore, the repression mechanism of TROM was also projected in the
physiological setting. In the HCC cohort, stratification of the data into recurrence and
non-recurrence samples showed that TROM expression level was high in the recurrence
samples. Interestingly, in those samples, the expression of HLA-DRA was relatively low.
When the dataset was now stratified according to the level TROM, we again found the
reversed correlation of HLA-DRA and TROM. Strikingly, samples with high level of
TROM and low level of HLA-DRA are the same samples that showed poor prognosis.
In breast cancer, histological cancer staging serves as benchmark for choosing the
optimal treatment for patients (7). However, grade II breast cancer tend to show mixed
prognostic outcome and treatment response, thus render the histological grading non-
effective for treatment options. Nonetheless, grade II breast cancer is the most frequently
presented cancer, occupying a 30-60% of total cases (32). Hence, the ability to predict
survival in this group of patients is crucial in providing additional information for the
clinicians in tailoring their treatment.  By using the level of TROM alone, we were able to
predict survival in grade II patients, segregating it into populations with good prognosis
(TROM-low) and bad prognosis (TROM-high). These results showed that TROM as a
promising prognostic marker, which could be used independently, or with other known
factors to get a better clinical picture of the type of cancer presented by patients.
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One surprising discovery found in this study is the relation of TROM to TP53.
p53  is a tumor suppressor that regulates carcinogenesis and its activation results in  cell-
cycle arrest and apoptosis, processes that eventually inhibit the growth of cells (33).
Somatic mutation of p53 occurs in 50% of all human cancer, while approximately 30% of
breast cancer samples bears the mutation (34). The association of p53 mutation status to
other clinico-pathological factors has been studied extensively in breast cancer. In the
Uppsala cancer cohort, we found that 80% of the breast cancer samples bearing mutated
p53 correlated with a high level of TROM expression (assigned as TOM-high).
Interestingly, the reversed correlation of HLA-DRA and TROM was only observed in
this group of samples. This observation alludes to the fact that TROM function on HLA-
DRA regulation could be a p53-dependent mechanism. In an ChIP on Chip study by
Weimann et al to search for new targets of E2F, TROM (FLJ11029) was found to be a
direct target of E2F (12) . This finding highlighted the possibility of a mutp53 droved
transcription pathway involving TROM. Upon p53 activation by stimuli (UV and -
irradiation), transcription of CDKN1A (p21) is turn on. p21 binds and inhibits cyclin
dependent kinases (CDKs) (35) , causing the hypophosphorylation of Rb, which, in turn,
prevents the release of E2F and blocks the following transcription pathway that drives
cell cycle progression. In the scenario where p53 is mutated, Rb is hyperphosphorylated
and E2F1 is free to transcript its target genes (36), including TROM (Figure 4.16). TP53
mutation detected by sequencing has strong prognostic significance, associating with ER
negativity, high histological grade and poor survival (8, 34).  Together, TROM’s
expression is elevated in these cancers, causing a low HLA-DRA and this is possibly the
major reason why these cancer suffering a poor prognosis. However, this hypothesis
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remains speculative and further investigation is needed to fully understand the
relationship between p53 and TROM.
Figure 4.17 Possible regulatory pathway of TROM by p53
Intact p53 activates p21CIP1 transcription upon stress stimulation by UV or -irradiation. p21CIP1 in
turn binds to and inhibits cyclin-dependent kinases, and causes hypoposphorylation of Rb. This
prevents the release of E2F to transcript its target genes. When p53  expression is disrupted, for
example by mutant p53 that acts as antagonist, the p21CIP1 pathway is perturbed and E2F is
released to transcript its target genes, which includes TROM. Thus, in mutp53 bearing
individuals, expression of TROM is high compared to wtp53 bearing individuals, causing a low
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4.4 Conclusion and future directions
In summary, the data presented here describe the characterisation of a novel and
low abundance gene that acts as a transcriptional regulator for MHCII, which also serves
as a prognostic marker for various cancers. TROM targeted the MHCII repression
through direct binding to the MHCII promoter, and subsequently affected the stability
of the enhanceosome via RFX and CREB. Upon IFN treatment, TROM also degraded
STAT1 and Y701p-STAT1, causing a cascading effect that led to the silencing of HLA-
DRA. Furthermore, the repression of HLA-DRA by TROM was complemented with
clinical data showing the repression in large cancer cohorts. Hence, the discovery of
TROM provides a new perspective on immunoescape, showing its importance in
deregulation of the immune system. Finally, we emphasized on the potential of TROM
as a predictive marker that should be exploited to facilitate better treatment option for
cancer patients
In future, we would like to explore the regulation pathway that caused the up-
regulation of TROM in the cancer cells. Specifically, we would like to study the direct
E2F regulation of TROM, and to examine how mutated p53 affects its transcription.
Furthermore, the potential of TROM as a prognostic marker will need to be
addressed in more cancer cohorts. For breast cancer, detail analysis of TROM’s
predictive power comparing to other established markers like HER2 and ER will be
performed. At the same time, evaluation of the prognosis power of TROM could be
analysed if it is dependent of the cell cycle genes, since TROM is regulated by E2F, a
potent regulator of cell cycle progression. Another confounding factor, cancer staging,
should also be normalised for the survival analysis.
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TROM mediating degradation of STAT1 needs further illustration, hence we could
examine the relationship of TROM to other known protein phosphatases of STAT1, for
example SHP1, SHP2, and TC45. To further analyse the ubiquitination of Y701 p-STAT1,
the relationship of TROM to the existing E3 ubiquitin ligase, SLIM should be given
priority.
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Appendix II  Comments from the examiners
Examiner No.1
This PhD thesis by Liu Bee Hui represents an excellent example of how making a
genomic approach to the analysis of human tumours can lead to interesting and
novel insights in cancer biology. In the first part of the thesis, the candidate
describes an interesting new technique (mSSH) where the previously-described SSH
protocol has been adapted for profiling on Affymetrix arrays. Using mSSH, a series of
upregulated transcripts common to breast, liver and NPC samples were identified.
This portion of the thesis has already been published in a leading cancer research
journal (Oncogene). In the second part of the thesis, the candidate has selected one
of these transcripts (TROM) for further functional characterization. They show that
TROM can function as a repressor of HLA-DRA expression, and demonstrate that this
repression can occur through at least two different mechanism: a) destabilization of
the HLA-DRA enhanceosome complex, and b) inhibition of JAK/STAT signalling
though interference of STAT1 activity.
In general, this thesis is well-written, and the data and figures are clearly presented
andinterpreted with the appropriate controls. This body of work also represents a
nice mix of different experimental techniques, ranging from microarray analysis,
molecular cloning, immunoflorecence microscopy, and clinical data analysis (eg
survival analysis). The candidate should also be commended fo rtaking on the
challenging task of a protein of “unknown function” (ie FLJ11029). I only have a few





This thesis focuses on developing a method to identify low abundance genes and to
use it to identify genes that are specifically deregulated in cancers. The candidate
has modified the existing SSH method for this purpose and has validated its
relevance using several cancer and normal tissue pairs.
In the second part of the thesis, the candidate has charactierized a gene (trom) that
is highly up-regulated in cancers, identified using this modified approach. The
candidate has then gone on the work-out the mechanisms of its actions in regulating
the expression of the MHC class II molecules.
On the whole, the thesis provides substantial amount of new information and
provides an advancement in knowledge, both in terms of improving the methodology
and charactering a novel gene (trom). It involves a combination of genomic work, as
well as cell and molecular biology techniques, which have been competently carried
out.
The data provided is clear and of good technical quality. It is noteworthy that the
first part of the work has been published, and the second part has been submitted,
highlighting the good quality of the data. As such, this thesis constitutes a
substantial body of important work that has set the stage for further in-dept analysis
of the significance of these findings.
Examiner No.3
Author developed an approach measuring the expression of low abundance gene
with SSH and Affymetrix expression array analyses. A gene, named TROM, was
identified and characterized as common up-regulated gene in HCC, NPC and breast
cancer. Part of the results has been published on July issue of ONCOGENE. Overall, it




Changes did to improve language and typo :
1. Page viii line 3, …in this physiological condition to…in cancer; line 18,
Endogenous TROM reciprocally… to Expression of endogenous TROM is
inversely correlated with respect to HLA-DRA’s expression in cells
treated with IFN, and in MHCII-deprived human tissues.
2. Page 3 and page 5 figure legends (now page 12 and page 14)…was excerpt
to was excerpted
3. Page 13 line 18 (now page 21 line 18), carrier to carriers
4. Page 14 line 1 (now page 22 line 1), randomised to randomized, deleted
resulted in
5. Page 15 line 1 (now page 5 line 1), pass to past; line 2 enable to enabled;
line 8 microarray to microarrays
6. Page 16 line 11 (now page 6 line 11), …are eliminated and hence
enrichment the selected cDNAs to…are eliminated and the selected
cDNAs enriched.
7. Page 20 line19 (now page 10 line 19), usesfulness to usefulness
8. Page 29 line 5 (now page 28 line 5), being to been; line 11…a novel, low
abundance and yet cancer-specific transcipt… to …a novel, cancer-
specific transcript that is low abundance.
9. Page 39 line 2 (now page 37 line 1), CNE2 to CNE2
10. Page 43 line 7 (now page 41 line 7), tawed to thawed; line 12 plaate to
plate
11. Page 45 line 13 (now page 43 line 13),tworeaction to two reactions; line
14 reation to reaction
12. Page 46 line 18 (now page 44 line 18), ata to at
13. Page 61 line 1 (now page 59 line 1), In quest to combine SSH…to To combine
SSH…; …challenge lays in generating
14. Page 91 line 7 (now page 91 line 7), Endogenous TROM reciprocally
expressed with respect to HLA-DRA…to Expression of endogenous
TROM is inversely correlated with HLA-DRA
15. Page 116 line 3 (now page 118 line 3), IFN was treated to CNE2 cells at
the indicated timepoint after the cells were transfected with TROM or
Section 4 Appendices
149
control vector to CNE2 cells were treated with IFN for the indicated
timepoints after TROM or empty vector transfections
16. Page 124 line 8 (now page 126 line 8), repressor to repressors; line 9
illuminate to immuminated
17. Page126 line 8 (now page 131 line 1), …to different extent to …to a
different extent; line1 CTIIA to CIITA; line 2 activatiors to activators
Answers to Examiner No. 1
Q1. As I understand it, the main use of the mSSH technique is to identify low-
abundance transcripts whose expression might be difficult to measure through
standard array analysis. However, there are many figures in Chapters 3 and 4 where
standard microarray analysis are mined to analysed their expression in tumours (eg
see Figures 3.6, 4.12, 4.13). If this is the case, doesn’t it mean that standard
microarrays are already sufficiently sensitive to detect these ‘low-abundance’
transcripts? The candidate might want to clarify this apparent contradiction.
A1. We use the standard microarray datasets to analysed expression of genes that
were isolated by mSSH, as in Figures 3.6, 4.12 and 4.24. In these datasets, a lot of
the genes isolated by mSSH were ‘absent’, hence we have to exclude the
conventional way of looking at the ‘present’ genes only, and analysed with the signal
intensities regardless of the  ‘absent-present’ calls of the genes. mSSH enhanced the
signal intensities of these low abundance genes that are cancer-specific, so that in
the mSSH microarray chips, they are all ‘present’.
Q2. The specific criteria used for selecting FLJ11029 for further functional
characterization would benefit from more detail. What was the specific fold change in
this gene in the three data sets? Was there anything else about this protein that
made it part of the “top10” list?
A2. As part of the 115 common genes that were up-regulated in all cancers, TROM
has to pass the filtering criteria of being up-regulated in over 70% of the sample
studied, or N10. More specifically, TROM was found up-regulated in 12 samples or
80% of the samples that we studied. It was also found consistently up-regulated in
various types of cancers using independent microarray databases as depicted in
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Figure 4.1. TROM was found to be up-regulated in HCC with 1.3 folds; 2.5 folds in
Breast cancer; and 2.8 folds in NPC. This is now incorporated in page 93 line 3 to
6;and line 9 to 10.
Q3. As mentioned by the candidate in the Introduction, there are other MHCII
dimmers besides HLA-DRA, and these related genes often have common
mechanisms of gene activation. Is there any evidence that TROM might also repress
these other HLA genes besides HLA-DRA? Can the microarray data sets be mined to
explore this possibility?
A3. HLA-DR, -DP and –DQ are classical MHCII molecules and they are regulated by
extremely similar promoters. Instead of using microarray database, we have
examined the level of these genes using real-time PCR. In the over-expression
experiments, we found that the transcription of HLA-DP and HLA-DQ were down-
regulated in CNE2 and MCF7 cell lines. However, HLA-DQ was up-regulated in

























































Q4.  The candidate shows that cells treated with TROM siRNA demonstrate an
enhancement of basal HLA-DRA transcription. How about under IFN-treated
conditions? Do TROM siRNAed cells exhibit a hyperactivation of HLA-DRA in response
to IFN treatment?
A4. As a separate event, cells treated with siRNA for TROM undergone apoptosis.
When these cells (TROM siRNAed) were treated with IFN, they undergone massive
apoptosis compared to cells treated with control siRNA. IFN is an inducer for
apoptosis, with the absence of TROM in the cells, the effect of IFN treatment is
augmented. Although we did not perform real-time PCR on these cells, we
hypothesised that cells treated with siRNA for TROM and treated with IFN would
have a hyperactivation of HLA-DRA.
Q5. I was a bit surprised that the promoter pull-down experiment in Figure 4.8
actually worked. As described on page 48, this experiment involves the incubation of
beads containing a specific DNA sequence with a cellular lysate, and then probing to
see which proteins bind to the sequence. Since DNA sequence is commonly
synthesized, it is totally devoid of chromatin or any other higher order architecture
that is commonly believed to be required for the formation of an enhanceosome
complex. Furthermore, since formation of the enhanceosome complex is IFN
dependent, the observation that the complex can still form on bead-attached DNA
must mean that some remnant of the IFN signal is still resident in the cellular
lysate, which is very unexpected. The authors might want to comment on this.
A5. Promoter pull down assay has been used repeatedly in experiments detecting
MHCII enhanceosome (1, 2) (3), both in IFN treated and non-treated cells. For the
pull down experiment shown in Figure 4.8, cells were treated with IFN for 24h prior
the assay, hence it is not surprising that the effect of IFN was still pronounced at
the point when the experiment was done. An illustration of how enhancosome could
form under the induction of IFN (4)  is shown below :
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Q6. An unresolved question is exactly where TROM is expressed in solid tumours. Do
the authors have evidence that it is indeed expressed in cancer cells, and not in
infiltrating immune cells?
A6. The clinical samples employed in our study were obtained from the tissue
depository of National Cancer Centre of Singapore.  The histology of these samples
was confirmed by qualified pathologists.  For the HCC and breast cancer samples,
they were ascertained to consist of more than 70% of the tumour tissues. For the
NPC samples, pathology assessment was not possible to rule out the intermingled
immune cells, due to the small size of the specimens. Furthermore, TROM’s
expression could be found in various non-immune related tumour cells lines (CNE2,
MCF7, PLC/PRF/5), confirming that the expression of TROM is indeed coming from
tumour and not from infiltrating immune cells. However, we cannot confirm the
expression of TROM in infiltrating immune cells for the immunohistochemistry of
TROM was not performed in tumour sections containing these cells.
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Q7. An interesting previous finding, stated in the Introduction, is the observation
that TROM is co-expressed with many other cell cycle gene and is potentially an E2F
target. This association which cell-cycle genes might explain the striking prognostic
power of TROM expression. Have the authors checked if the prognostic power of
TROM is dependent or independent from the cell cycle genes?
A6. TROM was found to be a novel target of E2F (5) and its expression associated
with cell cycle progression (6), hence it is highly possible that the prognostic power
of TROM is dependent on the cell cycle genes. This is an interesting and relevant
suggestion that we will carefully examine in our future study on TROM. In fact, in
synchronised HeLa cells, we found that TROM is highly expressed in late M phase,
indicating the role of TROM in cell cycle progression.
TROM
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Q8. In Figure 4.13, the authors check the association of TROM and HLA-DRA
expression in primary tumors. Have the authors explored the possibility of combining
both factors-> ie do patients with TROM high + HLA-DRA low tumors exhibit very
bad prognosis, as might be expected?
A8. Tumours exhibiting high expression of TROM (TROM-high) are having low
expression of HLA-DRA, and indeed these patients suffers a less preferable prognosis
than patients with low expression of TROM (TROM-low) and high expression of HLA-
DRA. This is now incorporated in page 123 line 12.
Q9. Another interesting finding in the breast cancer data set is that the inverse
relationship between TROM and HLA-DRA seems to be more pronounced in p53
mutant tumours. Have the authors validated this in any other datasets? Specifically,
the HCC dataset of Xin Chen et al (2002) has microarray data of liver cancers which
have also been checked for p53 status (expression)
A9. Dataset with p53 mutation status are rare. We had downloaded Xin Chen et al’s
data set from http//genome-www4.Stanford.edu/Microarray/SMD/index.html. with
much anticipation. Unfortunately, FLJ11029 was not to be found in their cDNA
microarray dataset, and the analysis could not be performed.
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Answers to Examiner No.2
Q1, 2 and 3. The candidate should improve on the language. Many parts contain
sentences that are not grammatically correct. To look through the whole thesis
carefully and make corrections. This is aptly highlighted even in the summary at the
beginning of the thesis (line 3; line 6 from bottom and line 3 from bottom). The
legends also do not “read” correctly in several instances (eg. Page3, page 5, etc)
A1, 2 and 3. Corrections have been made to improve the language of the thesis, as
listed in the earlier in the ‘changes to improve language and typo’.
Q4, 5 and 6. The Introduction section is the weakest of the whole thesis. It appears
to be put together without much thought, and reads “in parts” and does not flow.
The candidate starts with several cancers, goes on to the methodology and then talk
about MHCII and TROM, without explaining clearly why these topics have been
chosen. What is required is a revamp of the Introduction section to provide a proper
flow of thoughts. A suggestion is as follows: the need to identify low-abundance
genes -> comparison of methodologies -> its potential use in disease -> cancers ->
MHC and its role and regulation in cancers. The topic of TROM should be probably be
presented in the Discussion section, as it appears to be a misfit in the Introduction.
A4, 5 and 6. The Introduction was presented in such a way that it flows with the
aims and the topics of the study, ie to develop a method that could identify low
abundance genes followed by the characterization of a novel gene, which is a
transcription repressor of MHCII. Because both topics are under the general scope of
cancer, hence the statistical background of cancer was first discussed in the
introduction. However, the candidate regretted that the chapters of the Introduction
does not connect well and appears messy. Hence, amendments have been made
according to the examiner’s suggestion. The Introduction now reads in the direction
of: importance of low abundance genes-> comparison of methodologies -> cancers-
> MHCII and its role and regulation in cancers. Due to the lack of literatures on low
abundance genes, the introductory part of low abundance genes was combined
together with methodology to form one chapter. Furthermore, the topic of
TROM/FLJ11029 is now taken out from the introduction and presented in the
discussion part of section 3 (now page 126).
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Q 7. The justification of using 3 types of cancers is also not given. The Introduction
part on these 3 cancers is very brief and does not form a coherent essay, and the
reader does not get an idea of the major question that is being addressed by this
body of work at the start of the thesis (which appears to be focused on cancers).
There is a lot of emphasis on cancer in the beginning, but this thesis is about a novel
method, and characterization of a gene using some cancer tissues. So, it is not about
cancer primarily.
A7. The candidate does not agree with the examiner on this point. The central aim of
the work is to identify genes that are altered in cancer. To do so, the candidate first
developed a method (mSSH) that could complement the current gene profiling
assays on cancer to identify low abundance genes. Although this method has
potential use for other disease or biological system, it was developed with the hope
to facilitate the understanding of cancers. Secondly, the gene that was characterised
(TROM) was found to be constantly up-regulated in cancer, and the characterization
was done to illustrate the role of this gene in cancer. The role of TROM in cancer was
also validated using survival analysis on independent cancer dataset, showing the
relevance of the gene in carcinogenesis. Lastly, the use of three types of cancer is to
be able to identify both cancer-type specific genes, and the common genes that are
constantly up-regulated in all types of cancer. The rationale behind the usage of
three types of cancer is now in the Aims (now page 28 line 10).
Q8. An important point that is lacking the justification for the need to identify the low
abundance genes - which is not clearly spelt out. What is it that we are missing up
till now due to the lack of knowledge of low abundance genes? How will their
identification improve therapy, diagnosis, etc? What is the known utility, or
advancement that this knowledge has allowed so far, and will allow in future? Has
there been any other attempt to identify low abundance genes? Why is this method
better than others in the market?
A8. The answer for this question is now incorporated in the Introduction (now page
2-4)  and in the discussion of Section 3 (now page 84 line 13 onwards).
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Q9. How the % were worked out on page 64 needs to be clarified-e.g.732(39%),755
(44%), etc.
A9. The % were gotten by dividing the number of absent genes (732) before mSSH
to the number of present genes (1944 after adding up U133A and U133B chips) after
mSSH. For example, (732/1944) x 100% = 39%. This is now incorporated in page
62 line 22.
Q10. At the end of section, the conclusion does not dwell into the possible futuristic
use of the methodology. Hence, the discussion in this sense is lacking. The candidate
could add on the possible applications of this new modified method in other
aspects/areas of biology.
A10. A paragraph was added to compare the current technology that could identify
low abundance genes, and the advantage of mSSH over them. Some discussion was
added on possible usage of mSSH in other areas of biology (now page 84 line 13).
Q11 &12. The second part on characterization of TROM suggest an inverse
correlation between TROM and MHC class II expression in cancer tissues. This is
confirmed by several methods. However, in the Introduction, it has been indicated
that MHC class II is often expressed in Antigen Presenting Cells (APCs). In this
respect, liver, breast and NPC tissues are not generally APCs. Thus, why would TROM
be specifically overexpressed in cancerous tissues of these cell types to suppress
MHC Class II? Explanations need to be given. Why did the candidate not compare
existing databases of APC-cancers (eg B cell lymphomas) for correlation between
TROM and Class II levels? This should be included.
A11 & 12.
Endogenous TROM is high in MHCII deprived tissues, while relatively low in adult
organs. When compared to the normal tissues adjacent to the tumour, the level of
TROM was expressed higher in the cancerous tissues, even though these tissues had
arisen from the same organ site. Tumour cells expressed Tumour Antigens (TA)
which are not found on normal tissues. These antigen is presented via both MHC
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class I and class II molecules, and activate both CD4+ and CD8+ T cells (7).
Specifically for MHC class II, the TAs are gp100 (8), MAGE-1,MAGE-3 (9), Tyrosinase
(10) and NY-ESO-1 (11). By suppressing the expression of MHCII, these TA could
not be presented to the CD4+ T cells, which in turns would lead to the inactivation of
the cytolytic pathway. Hence, by over-expressing TROM in cancer cells, the immune
surveillance system is suppressed. We would compare the level of TROM and MHCII
in APC-cancer in our future studies to present a clearer picture of the correlation
between the two molecules. This is now incorporated in page 135 line 24.
Q13. Is there any correlation between TROM and MHC class I, which is also often lost
in cancers?
A13. Realtime PCR on TROM siRNAed cells showed that the level of MHC class I is not
affected by TROM. This result is incorporated in Figure 4.6b (Figure 4.6 is now
changed to Figure 4.6a) on page 106.
Q14. More justification is required for trying to correlate MHC class II and TROM,
beside the fact that its zinc-binding domain has high homology to a repressor of
MHC, NFX1.
 A14. The protein sequence of TROM does not match any known proteins in the
public database. However, its zinc-binding domain has a 60% homology to that of
NFX1, a repressor of MHC class II. Besides this, TROM was found to be highly
expressed in T-cells by Abbas et al (12), which is deprived of MHC class II. This is
now in the discussion of section 3. Page 126 line 18.
Q15. The second part showing that TROM expression probably leads to Stat1
degradation/ dephosphorylation is weak. There is little data to confirm this
statement. At best, these are correlative data, and no direct evidence has been
shown that TROM is indeed involved in degradation of phosphorylated Stat1. hence,
this section needs to be worded carefully, not to overstate the claims.
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A15. To strengthen the result on Stat1 degradation by TROM, we have now included
the result of a half life analysis of Stat1 in Figure 4.10d (page 117), showing that in
the presence of TROM, half life of Stat1 is much shorter compared to the controls. To
avoid over statement, the discussion part of section 3 (page 132 line 12) was
changed from ‘The presence of TROM could be inducing the degradation of STAT1
protein upon IFN treatment. Further investigation showed that indeed STAT1 was
being degraded and could be rescued by MG132 and lactacystin, two inhibitors of the
proteosomal degradation pathway’ to ‘We hypothesized that the presence of TROM
could be inducing the degradation of STAT1 protein upon IFN treatment. Confocal
analysis showed that when cells were treated with MG132 and lactacystin, two
inhibitors of the proteosomal degradation pathway, the degradation of STAT1
mediated by TROM was rescued. However, further investigation is needed to
illustrate the exact mechanism by which TROM mediates STAT1 degradation’.
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Answers to examiner No. 3
Q1. It seems the author miss interpreted “expression signature” on page 8.
Expression signature is not identifying genes that are differentially expressed
between two populations. Expression signature is the combination of a set of genes
that can be used as a measurement of clinical phenotypes. It looks at entire genome
as a whole and uses the signature as a biomarker. Low abundance genes might not
be a good indicator of signature. On the other hand, SSH was developed in
1996,which was before the power of genome-wide profiling. For measuring low
abundance gene, the next generation technology is “The Solexa Sequencing
technology” using Illumina GAII facility. However, it is not necessary to criticize the
method here, as TROM has been identified through this approach. It would be great
to add a little bit discussion about the new technology.
A1. The candidate agreed with the examiner on the definition of ‘gene signature’. On
page 8 (now page 4), ‘gene signatures’ is now changed to ‘genetic profiles’ However,
we did call the genes identified by mSSH as ‘gene signatures’ because they are able
to segregate tumour from normal in independent microarray data sets. The
discussion on next-generation sequencing techniques, including Solexa, was added
to the discussion of Section 3 (page 84 line 13).
Q2. Not sure why looked at genes that are highly expressed in all kinds of cancer,
instead of finding genes that are cell type specific. Also, author should aware that
recurrence or prognosis is affected by multiple factors, such as expression and copy
number abnormalities in cancer cells, as well as host genetic variations. Probably all
these are beyond the scope of this study, but could be one of the future directions,
and it would be better to discuss these points a little bit in Introduction or discussion
section.
A2. The candidate would like to look at common causal genes underlying cancer
formation, hence the characterization of a gene from the common gene list. The
elevated level of TROM in recurrence samples and its prognosis power in cancer
samples are additional observations that could add to the value of this gene.
However, study of recurrence and prognosis is not the main focus of this thesis.
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Nonetheless it would be interesting to analyse the function of TROM in recurrence in
our future studies.
Q3. A bit concern about the statistical power of this study. On page 59, there were
only 5 HCC, 4 NPC and 5 breast cancer samples, how would author ensure the
replication? Also, how did author define “Normal” tissue, the histological normal? It
might be a mixed cell types. The expression level in this adjacent “normal” biopsy
might actually reflect the expression of activated micro-enviroment, but is not from
the “normal” cells. Should use laser capture microdissection for the extraction of
cancer adjacent normal cells? However there is no discussion regarding cancer
adjacent normal tissue in this thesis.
A3. Each mSSH profile is comparable to one library from conventional SSH.
Conventionally, only one subtraction (one library) will be perform for a gene profiling
project. In our study, we did 14 mSSH subtractions that are comparable to 14
libraries for our gene profiling project. Hence the genes isolated are robust and could
be validated both real-time PCR and in silico (hierarchical clustering) studies. Laser
capture microdissection (LCM) is similar in function with mSSH to isolate tumour
cells. In mSSH, the normals used in this study have been obtained from the tissue
bank of National Cancer Centre, after careful certification by qualified pathologist.
Q4.  On page 96, author reported a micro deletion at 5’ UTR and micro insertion at
3’UTR. Were those homozygous or heterozegous indels? Did those indels cause
alternative splicing? Could insertion at 3’ UTR introduce micro-RNA binding site(s),
affecting protein level? Again, it could be discussed in the section of future direction.
A4. This is an interesting observation that the candidate would like to study in future.
Q5. Those are well designed experiments and great work from page 97 to 117.




a. How did author define TROM low vs TROM high, the median level?
b. The stage would be a major confounding factor of the survival analysis, since
TROM was higher expressed in late stage tumor. The survival analysis should
adjust cofounders.
c. If TROM was higher expressed in late stage, then, what is the better
prognosis marker, stage or TROM expression? Could author compare these
two markers?
d. For HCC recurrence, were those patients treated with same chemo?
e. For the prognosis of breast cancer, how about the cell types, ER+/-, Her2+/-?
Those are great markers of breast cancer. Author should look more closely to
each subtype of breast cancer. For example, could TROM expression predict
outcome of patients with ER- or Her2- or triple negative? That could further
lift the impact of this study.
A5.
a. Cancer datasets were stratified to TROM low vs TROM high according to the
mean level of TROM in the datasets (page 122 line 3).
b. Survival analyses were performed without knowledge of the stages for the
samples studied. However it will be beneficial to adjust the staging in future
analysis.
c. In breast cancer dataset, TROM proved to be a better marker than stages in
Grade II cancers (Figure 4.2 page 121). This is also stated in page 122 line
22.
d. The information of the therapy treated to the patients was not given in the
HCC paper which the dataset was downloaded (13).
e. This is an excellent suggestion for future study at TROM, and on its prognosis
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